
==== Front
J Transl Med
J Transl Med
Journal of Translational Medicine
1479-5876
BioMed Central London

5634
10.1186/s12967-024-05634-5
Research
Altered methylation of imprinted genes in neuroblastoma: implications for prognostic refinement
Suman Medha 1
Löfgren Maja 1
Fransson Susanne 2
Yousuf Jewahri Idris 1
Svensson Johanna 2
Djos Anna 2
Martinsson Tommy 2
Kogner Per 3
Kling Teresia 1
http://orcid.org/0000-0002-8584-555X
Carén Helena helena.caren@gu.se

1
1 https://ror.org/01tm6cn81 grid.8761.8 0000 0000 9919 9582 Sahlgrenska Center for Cancer Research, Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Medicinaregatan 1F, 405 30 Gothenburg, Sweden
2 https://ror.org/01tm6cn81 grid.8761.8 0000 0000 9919 9582 Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
3 https://ror.org/056d84691 grid.4714.6 0000 0004 1937 0626 Childhood Cancer Research Unit, Women’s, and Children’s Health, Karolinska Institutet, Stockholm, Sweden
31 8 2024
31 8 2024
2024
22 80817 6 2024
22 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Neuroblastoma (NB) is a complex disease, and the current understanding of NB biology is limited. Deregulation in genomic imprinting is a common event in malignancy. Since imprinted genes play crucial roles in early fetal growth and development, their role in NB pathogenesis could be suggested.

Methods

We examined alterations in DNA methylation patterns of 369 NB tumours at 49 imprinted differentially methylated regions (DMRs) and assessed its association with overall survival probabilities and selected clinical and genomic features of the tumours. In addition, an integrated analysis of DNA methylation and allele-specific copy number alterations (CNAs) was performed, to understand the correlation between the two molecular events.

Results

Several imprinted regions with aberrant methylation patterns in NB were identified. Regions that underwent loss of methylation in > 30% of NB samples were DMRs annotated to the genes NDN, SNRPN, IGF2, MAGEL2 and HTR5A and regions with gain of methylation were NNAT, RB1 and GPR1. Methylation alterations at six of the 49 imprinted DMRs were statistically significantly associated with reduced overall survival: MIR886, RB1, NNAT/BLCAP, MAGEL2, MKRN3 and INPP5F. RB1, NNAT/BLCAP and MKRN3 were further able to stratify low-risk NB tumours i.e. tumours that lacked MYCN amplification and 11q deletion into risk groups. Methylation alterations at NNAT/BLCAP, MAGEL2 and MIR886 predicted risk independently of MYCN amplification or 11q deletion and age at diagnosis. Investigation of the allele-specific CNAs demonstrated that the imprinted regions that displayed most alterations in NB tumours harbor true epigenetic changes and are not result of the underlying CNAs.

Conclusions

Aberrant methylation in imprinted regions is frequently occurring in NB tumours and several of these regions have independent prognostic value. Thus, these could serve as potentially important clinical epigenetic markers to identify individuals with adverse prognosis. Incorporation of methylation status of these regions together with the established risk predictors may further refine the prognostication of NB patients.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12967-024-05634-5.

Keywords

Neuroblastoma
Genomic imprinting
DNA methylation
Copy number alterations
http://dx.doi.org/10.13039/501100002794 Cancerfonden http://dx.doi.org/10.13039/501100004359 Vetenskapsrådet Sahlgrenska University hospital and Laboratory medicine research and development granthttp://dx.doi.org/10.13039/501100006313 Barncancerfonden University of GothenburgOpen access funding provided by University of Gothenburg.

issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Neuroblastoma (NB) is an aggressive childhood malignancy that originates from immature cells of the neural crest with primary tumours commonly arising in adrenal medulla or in paraspinal sympathetic ganglia. NB accounts for 8–10% of all childhood cancer cases and is the most common form of cancer that affects infants (median age at diagnosis 17 months) [1]. NB is a heterogeneous disease with diverse biological and clinical features, ranging from low-risk localized cases that show spontaneous regression without any treatment to high-risk NB (HR-NB) cases featuring widely metastatic tumours with frequent adverse outcome [2]. The outcome for children with HR-NB, constituting almost half of all NB cases remains poor (5-year overall survival rate < 50%) despite an intense multi-modal treatment regime. The outcome is even worse for patients with relapsed or refractory disease (survival rate < 10%), as the cure for relapsed cases is limited [3]. Although advances in treatment have been made, management of HR-NB patients is especially challenging given the young age of patients, disease heterogeneity, treatment resistance and organ toxicity. Furthermore, survivors of this aggressive multi-modal therapy still remain at risk for long-term complications that can lead to excess morbidity, premature mortality, and impaired quality of life.

The genomic landscape of NB is well-studied with only a few genes shown to be altered recurrently by somatic genetic events, where mutations in ALK, encoding a receptor tyrosine kinase, being the most frequent; ~ 10% at primary diagnosis [4–6] and in 20–43% of patients with relapsed or refractory NB [7–9]. Instead of events affecting single genes, genetic alterations in NB predominantly harbour copy number alterations (CNAs) where HR-NB are associated with MYCN amplification or 11q deletion, and a higher rate of other segmental chromosomal aberrations including 1p deletion and 17q gain [10, 11]. However, the mechanisms that triggers the accumulation of chromosomal alterations leading to NB at such an early age is still not clear, and only a few specific genes in regions affected by recurrent segmental aberrations are identified to have clinical and therapeutic impact (e.g. ALK, TERT, ATRX or CDKN2A/B) [12–15].

Impairment of the normal sympathoadrenal differentiation is critical for NB development, meaning that NB retains embryonic features, which ultimately promote intratumour heterogeneity and resistance to therapy [16]. Molecular clock analysis suggests that NB starts developing as early as the first trimester of pregnancy where early genomic instability and prolonged evolution is associated with aggressive disease and, that aneuploidy is present at an early stage [17]. Furthermore, recent studies on foetal developmental trajectories and tumoural transcriptional cell state indicate that low-risk NB mainly associates to highly differentiated sympathoblasts whereas HR-NB associates to earlier developmental time points [18, 19]. This further supports that subversion of the normal differentiation process is critical for NB development and that deregulation of genes important for embryonal growth and development could provide an early hit that may lead to accumulation of further downstream molecular events.

Genomic imprinting is a mechanism in which a small group of genes (~ 1%) are expressed in a parent-of-origin specific manner [20]. To date, around 150 imprinted genes have been reported in humans of which many have major roles in early foetal growth and development. The mono-allelic expression of imprinted genes is regulated by a differential methylation pattern at respective parental allele that are inherited and maintained throughout the somatic development. Any aberration (genetic or epigenetic) in these regions may lead to loss of imprinting (LOI), which is associated with a range of human disorders. Some of the well-known examples are Angelman Syndrome (functional loss of the maternally active UBE3A allele), Prader-Willi Syndrome (loss of genes under control of the paternally active SNURF-SNRPN promoter) and Beckwith-Wiedemann Syndrome (LOI within the chromosome 11p15.5 region) [21]. LOI has also been reported as a common and early event in several adult tumours including colorectal cancer, liver cancer and in leukemia [22–24], with imprinting aberrations showing potential prognostic [24] and diagnostic value [25]. These findings suggest the importance of the imprinting mechanism and its role in tumour initiation and progression.

Enhancing the knowledge about NB pathogenesis is crucial, as there is an urgent need to develop an effective and less toxic way of treating the disease. This could possibly be achieved by a deeper understanding of the disease pathology and the identification of molecular alterations and pathways in NB pathogenesis that can be targeted. The notable lack of identified driving events in some NB tumours imply an additional layer of dysregulation and thus, a critical question is which other aberrations subvert normal development, cause NB, or add to heterogenous tumour behaviour. As imprinting have been implicated in tumour initiation and progression in other malignancies, we studied the DNA methylation landscape of NB with a focus on imprinted regions to identify regions with altered methylation patterns. Identification of dysregulated imprinted loci in NB tumour samples will enhance our understanding of the disease biology and potentially lead to the identification of molecular markers for novel treatment approaches.

Materials and methods

Study samples

The samples included in this study were obtained from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and German Neuroblastoma Trial, merged as discovery set and a local cohort of NB tumours, used as validation set as described below.

Public datasets

NB cases in TARGET were diagnosed between the years 1995–2011 and the age at diagnosis ranged from 0 to 20 years (median age 3 years). The tumours were diagnosed as stage 1 (8%), stage 2 (0.5%), stage 3 (3%) and stage 4/4 s (89%) according to the International Neuroblastoma Staging System (INSS). The tumours were mainly undifferentiated or poorly differentiated (79%) and most cases fell into the high-risk group (79%) according to the Children’s Oncology Group (COG) risk classification. MYCN amplification was seen in 25% of the cases and 11q deletion was seen in 38% of the cases. There were 93 deaths recorded during follow-up (median [IQR]: 7 [0–15] years). In the German Neuroblastoma Trial, cases were diagnosed between 1997 and 2004 and have been previously described [26]. Most of the cases in this cohort were diagnosed as stage 4/4 s tumours (73%), while the remaining were diagnosed as stage 3 (9%), stage 2 (9%) and stage 1 tumour (9%). The tumours were grouped as high-risk (56%), intermediate-risk (7%) and low-risk (37%). Amplification of MYCN was observed in 33% of cases while 27% had 11q deletion.

DNA methylation data (IDAT files) for primary NB (n = 213) samples was obtained from the TARGET-NB project (Study Accession: phs000467). For the German Neuroblastoma Trial (NB97 and NB2004), DNA methylation data was also obtained for 105 NB cases from Gene Expression Omnibus (GEO) GSE73515. For both the public datasets, genome-wide DNA methylation was assessed using the Infinium HumanMethylation450 BeadChip. Data from the two studies were merged and treated as the discovery set. For samples in the TARGET dataset, single nucleotide polymorphism (SNP) array data generated on three different Illumina platforms; HumanHap550, Human610-Quad and HumanOmniExpress from tumour and matching blood were downloaded from GSE131189 for 122/207 (59%) matching cases. Clinical and genomic data of the study participants are presented in Table 1.Table 1 Clinical and pathological features of the study participants in the discovery and validation sets

Sample characteristics	Discovery set (n = 284)	Validation set (n = 85)	
TARGET NB (n = 185)	German Neuroblastoma Trial (n = 99)	Local NB Cohort (n = 85)	
Median age at diagnosis (years), interquartile range	3.0 [25%; 1.7]	Missing	2.0 [25%, 0.9]	
< 1.5 years (n, %)

≥ 1.5 years (n, %)

	37 (20)

148 (80)

	57 (58)

42 (42)

	32 (38)

53 (62)

	
Gender (n, %)	
Male

Female

	113 (61)

72 (39)

	Missing	33 (39)

52 (61)

	
Tumour stage (n, %), INSS	
Stage 1

Stage 2

Stage 3

Stage 4

Stage 4 s

Unknown

	14 (8)

1 (0.5)

6 (3)

146 (79)

18 (10)

–

	9 (9)

9 (9)

9 (9)

72 (54)

19 (19)

–

	2 (2)

8 (9)

13 (15)

33 (39)

3 (4)

26 (31)

	
Tumour grade (n, %)	
Differentiating

Undifferentiated or poorly differentiated

Unknown

	10 (5)

146 (79)

29 (16)

	Missing	Missing	
COG Risk group (n, %)	
High risk

Intermediate risk

Low risk

	147 (79)

9 (5)

29 (16)

	55 (56)

7 (7)

37 (37)

	Missing	
MYCN status (n, %)	
Amplified

Not amplified

Unknown

	47 (25)

138 (75)

–

	33 (33)

66 (67)

–

	28 (33)

56 (66)

1 (1)

	
11q deletion (n, %)	
11q deleted

11q normal

Whole chromosome 11 gain

Whole chromosome 11 loss

Unknown

	70 (38)

114 (62)

–

–

1 (0.5)

	27 (27)

48 (48)

1 (1)

23 (23)

–

	20 (23)

64 (75)

–

–

1 (1.1)

	
TARGET therapeutically applicable research to generate effective treatments, NB neuroblastoma, INSS international neuroblastoma staging system, COG Children’s Oncology Group

Validation cohort

The local cohort used as a validation set in this study included 85 NB tumours from a local cohort diagnosed between 1986 and 2023. Age of diagnosis ranged from 0 to 19 years (median age 2 years). Similar to the discovery set, most of the cases in the local cohort were higher stage tumours with 41% of tumours diagnosed as stage 4/4 s, 15% as stage 3, 9% stage 2 and 7% as stage 1. Tumour stage was unknown for 31% of the NB cases. A total of 34 deaths were recorded in the local cohort. Amplification of MYCN was observed in 32% of the cases while 11q deletion was observed in 23% of the cases in the local cohort. The clinical and pathological characteristics of the study participants are summarized in Table 1.

DNA methylation data for cases in the local cohort was assessed on three different methylation arrays: Illumina Infinium HumanMethylation450 (HM450K) array (n = 49) [27], EPIC array (n = 32) and EPIC array v2.0 (n = 4).

For investigation of normal tissue, healthy foetal adrenal gland tissue (n = 11) was used as controls and methylation data (Normalized methylation levels, beta-value) were obtained from Gene Expression Omnibus (GEO) GSE56515, n = 9 and GSE54719, n = 2. Methylation data from samples with maternal uniparental diploidy (mUPD) (n = 1) and paternal UPD (pUPD) (n = 2), used for visualization was obtained from GSE103738.

Sample exclusion based on the copy number alteration profile

We used publicly available data from the samples included in the TARGET dataset (n = 216) and the German Neuroblastoma Trial (n = 105) as discovery set and a local cohort of samples as validation set (n = 97). Manual inspection of CNA plots was performed and only cases with distinct change at segmental alterations were kept in order to retain samples with increased likelihood for higher degree of neoplastic cells. After manual inspection of CNA-profiles, 26/213 cases from TARGET, 6/105 cases from the German Trial study and 12/97 cases from the local cohort were removed with suspicion of low tumour cell content and the reduced cohort sizes of n = 185, n = 99 and n = 85 for respective cohorts were used for further analyses. Copy number alteration plots using the methylation array data were generated using the R package conumee [28].

Data preprocessing and normalization

Methylation array data

Methylation data for samples in the discovery set was preprocessed and normalized together to account for potential batch effects between the datasets. Raw methylation intensity files (IDATs) were imported into the R computing environment and data was pre-processed and normalised, using normalisation method “noobBMIQ” using the R package ChAMP [29]. Data quality was first accessed using parameters including detection P-value and bead count, which were calculated for every CpG position in every sample. Probes with an average detection P-value of > 0.01 were considered unreliable and were removed from further analysis. CpG probes that aligned to multiple sites and with a bead count of < 3 were also removed. Samples with failed p-value of > 0.05 were removed from further analysis. After data pre-processing and normalization, 284 out of 287 cases and a total of 438,729 CpG sites remained for further analysis. Beta-values (ratio of the methylated probe intensity and the sum of methylated and unmethylated probe intensity) were calculated for all the NB cases. For the validation dataset, data from different methylation array platforms were pre-processed and normalised separately and beta-values at common probes were merged. The same thresholds for data filtering were applied for the validation set. After data pre-processing 85 cases remained for further analysis.

SNP array data

Processed SNP array data (TXT files) from tumour and matching blood were downloaded from GSE131189 for 105/185 (57%) matching cases in the TARGET dataset. SNP data was generated using three different Illumina chips: HumanHap550, Human610-Quad and HumanOmniExpress with a common set of 316,210 probes.

Imprinting regions analysis and interpretation

Imprinted DMRs are defined as regions in the genome that show differences in DNA methylation between the two alleles. At these regions one allele is completely methylated while the other remains unmethylated, which is dependent on the parent of origin. Therefore, in a normal state the expected methylation beta-value (assessed on methylation array) at imprinted DMRs, is expected to be ~ 0.5 and any deviation from this i.e., gain or loss of methylation levels indicates imprinting dysregulation.

For studying imprinting deregulation in NB, we focused on 49 of the 50 known imprinted DMRs previously reported by Mora et al. (2018) [30]. This study compared the methylation profiles of normal biparental and reciprocal uniparental diploidy samples and reported 789 CpG probes mapping to 50 known imprinted DMRs. Out of 789 CpG probes, 704 CpG positions overlapping 49 imprinted DMRs were overlapping with the NB and foetal adrenal methylation data and thus were further investigated in this study.

Herein, we name the imprinted DMRs based on the genes that are mapping to that region (Table 2). Names of all the genes are used in the nomenclature if a region was associated with more than one gene. For example, NNAT:TSS-DMR that maps to the genes NNAT and BLAP is named as NNAT/BLAP. DMRs that do not overlap any gene or overlap a pseudogene are named as the original DMR name. Similarly, when the overlapping gene is common between two or more DMRs, the original DMR name is used in the nomenclature.Table 2 Genomic location and overlapping gene names and function of the imprinted differentially methylated regions (DMRs)

Imprinted DMRs	Methylated Allele	Chr	Region covered	No of CpG	Overlapping genes	Gene function	Role in cancer/other disease	
PPIEL:Ex1-DMR	M	1	Chr1:40024971–40025415	4	LOC728448	Pseudogene	–	
DIRAS3:Ex2-DMR	M	1	Chr1:68512539–68513063	8	DIRAS3	Tumour suppressor	Downregulated in multiple cancers [59, 60]	
DIRAS3:TSS-DMR	M	1	Chr1:68515788–68517273	21	DIRAS3	As above	As above	
GPR1-AS:TSS-DMR	M	2	Chr2:207068254–207068409	2	GPR1	Neuronal stem-cell proliferation and differentiation	Promotes cancer cell proliferation and invasion [61, 62]	
ZDBF2/GPR1:IG-DMR	P	2	Chr2:207116070–207129158	8	–	–	–	
NAP1L5:TSS-DMR	M	4	Chr4:89618533–89619236	14	NAP1L5; HERC3	NAP1L5: Promotes proliferation of neural progenitors and inhibits neuronal differentiation during cortical development

HERC3: ligase and ubiquitin-protein transferase activity

	NAP1L5: Potential tumour suppressor in hepatocellular carcinomas [63]

HERC3: Potential tumour suppressor in colorectal cancer [64]

	
VTRNA2-1:DMR	M	5	Chr5:135414858–135416613	17	MIR886	Cell growth regulation	Often hypermethylated and repressed in cancer [65–67]	
FAM50B:TSS-DMR	M	6	Chr6:3849095–3850106	24	FAM50B	Role in the circadian clock	–	
PLAGL1:alt-TSS-DMR	M	6	Chr6:144328421–144329887	14	HYMAI; PLAGL1	HYMAI: non-coding

PLAGL1: Transcriptional activator. Encodes a C2H2 zinc finger protein that functions as a suppressor of cell growth

	Transient neonatal diabetes mellitus [68]	
IGF2R:Int2-DMR	M	6	Chr6:160427501	1	IGF2R	G protein-coupled receptor activity and enzyme binding		
WDR27:Int13-DMR	M	6	Chr6:170054730–170055332	2	WDR27	Cell signalling	–	
GRB10:alt-TSS-DMR	M	7	Chr7:50849168–50850870	8	GRB10	Insulin receptor signalling cascade and nervous system development	Novel oncogene in glioma [69]	
PEG10:TSS-DMR	M	7	Chr7:94285642–94287242	50	SGCE; PEG10	SGCE: calcium ion binding

PEG10: cell proliferation, differentiation, and apoptosis

	PEG10: Overexpressed in several cancers and promotes tumor progression [70–73]	
MEST:alt-TSS-DMR	M	7	Chr7:130130122–130133110	54	MESTIT1; MEST	MESTIT1: non-coding RNA involved in the regulation of MEST expression during development

MEST: embryo development

	MESTIT1: Deregulated in breast cancer and promotes cancer progression [74]

MEST: esophageal squamous cell carcinoma [75]

	
SVOPL:alt-TSS-DMR	M	7	Chr7:138348774–138348981	2	SVOPL	Transmembrane transporter activity	Breast cancer [76], colorectal cancer [77]	
HTR5A:TSS-DMR	M	7	Chr7:154862770–154863381	6	HTR5A	Functions as a neurotransmitter	Downregulated in high grade glioma [78]	
ERLIN2:Int6-DMR	M	8	Chr8:37605359–37605978	7	LOC728024; ERLIN2	LOC728024: Pseudogene

ERLIN2: cell cycle progression

	ERLIN2: Overexpressed in aggressive breast cancer and promotes tumour growth [79]	
PEG13:TSS-DMR	M	8	Chr8:141108607–141110900	7	TRAPPC9	NF-kappa-B signaling and neuronal cells differentiation	Promotes tumourigenesis in cancer cells [80]	
FANCC:Int1-DMR	M	9	Chr9:98075492	1	FANCC	Maintenance of normal chromosome stability	–	
INPP5F:Int2-DMR	M	10	Chr10:121578137–121578639	4	INPP5F	Phosphoric ester hydrolase activity	Potential tumour suppressor in glioblastoma [81]	
H19/IGF2:IG-DMR	P	11	Chr11:2019079–2024126	43	H19; MIR675	H19: Long non-coding RNA

MIR675: post-transcriptional regulation of gene expression

	H19: Overexpressed in multiple cancers and facilitates several cellular processes including cell proliferation, migration, invasion [82–84]

MIR675: predicted target of H19 [85]

	
IGF2:Ex9-DMR	M	11	Chr11:2153991–2154952	9	INS-IGF2; IGF2	INS-IGF2: AMP-activated protein kinase signaling

IGF2: growth factor activity

	INS-IGF2: promotes cell proliferation in lung cancer [86]

IGF2: Overexpressed in multiple cancers and associated with poor prognosis [87–90]

	
IGF2:alt-TSS-DMR	M	11	Chr11:2168625	1	IGF2AS; INS-IGF2	IGF2AS: RNA gene

INS-IGF2: As above

	IGF2AS: potential tumour suppressor in prostate cancer [91]	
KCNQ1OT1:TSS-DMR	M	11	Chr11:2720229–2722195	26	KCNQ1; KCNQ1OT1	KCNQ1: Transmembrane transporter binding

KCNQ1OT1: long non-coding RNA that regulates transcription of multiple target genes

	KCNQ1OT1: acts as an oncogene in colon cancer [92]	
RB1:Int2-DMR	M	13	Chr13:48892551–48895478	13	RB1	Negative regulator of cell cycle	Tumour suppressor, deregulated in multiple cancers [39, 93–97]	
MEG3:TSS-DMR	P	14	Chr14:101290556–101293856	32	MEG3	Interacts with the tumour suppressor p53 and regulates p53 target gene expression	Deregulated in multiple cancers [98]	
MEG8:Int2-DMR	M	14	Chr14:101370989	1	MEG8	Long non-coding RNA	Involved in cancer progression in multiple cancers [99]	
MKRN3:TSS-DMR	M	15	Chr15:23807180–23812334	11	MKRN3	Ligase activity	Tumour suppressor frequently mutated in non–small cell lung cancer [100]	
MAGEL2:TSS-DMR	M	15	Chr15:23892574–23893742	6	MAGEL2	Ubiquitin-protein transferase activity	Downregulated and associated with poor prognosis in glioma [101]	
NDN:TSS-DMR	M	15	Chr15:23931451–23932758	8	NDN	Growth suppressor, also interacts with p53 and works in an additive manner to inhibit cell growth	Tumour suppressor [41, 102]	
SNRPN:alt-TSS-DMR	M	15	Chr15:25068738–25069376	7	SNRPN	pre-mRNA processing and tissue-specific alternative splicing	Promotes tumour proliferation and migration in colorectal cancer [103]	
SNRPN:Int1-DMR1	M	15	Chr15:25,093,244–25093521	4	SNRPN	As above	As above	
SNRPN:Int1-DMR2	M	15	Chr15:25123287–25123688	4	SNRPN	As above	As above	
SNURF:TSS-DMR	M	15	Chr15:25200253–25201732	6	SNRPN, SNURF	SNURF: Processing of Capped Intron-Containing Pre-mRNA	SNURF: Breast cancer [104]	
IGF1R:Int2-DMR	M	15	Chr15:99408636–99409506	7	IGF1R	Tyrosine kinase activity	Cancer promoting in lung cancer [105]	
ZNF597:3' DMR	M	16	Chr16:3481970–3482078	2	–	–	–	
ZNF597:TSS-DMR	P	16	Chr16:3493133–3494155	12	ZNF597; NAT15	ZNF597: nucleic acid binding

NAT15: acyltransferase activity

	–	
ZNF331:alt-TSS-DMR1	M	19	Chr19:54040774–54042165	12	ZNF331	Nucleic acid binding	Novel tumour suppressor in gastric cancer and potential biomarker in colorectal cancer detection [106, 107]	
ZNF331:alt-TSS-DMR2	M	19	Chr19:54057208–54058085	4	ZNF331	As above	As above	
PEG3:TSS-DMR	M	19	Chr19:57349204–57352785	34	ZIM2; PEG3; MIMT1	ZIM2, PEG3: transcriptional regulation	–	
MCTS2P:TSS-DMR	M	20	Chr20:30134929–30135362	8	HM13; PSIMCT-1	HM13: Protein homodimerization activity and peptidase activity

PSIMCT-1: Pseudogene

	HM13: Potential predictive biomarker in hepatocellular carcinoma [108]	
NNAT:TSS-DMR	M	20	Chr20:36148604–36150061	36	BLCAP; NNAT	BLCAP: reduces cell growth by stimulating apoptosis

NNAT: Maturation or maintenance of the overall structure of the nervous system

	BLCAP: acts as tumour suppressor gene in many cancers [109, 110]

NNAT: altered in several cancers including non-small cell lung cancer [111], glioblastoma [112], medulloblastoma [113], neuroblastoma [38]

	
L3MBTL1:alt-TSS-DMR	M	20	Chr20:42142417–42143502	26	L3MBTL	Function as methyl-lysine readers, associated with the repression of gene expression	Candidate tumour suppressor gene myeloid cancers [114]	
GNAS-NESP:TSS-DMR	P	20	Chr20:57414039–57418015	21	GNASAS; GNAS	GNASAS: long non-coding RNA

GNAS-GTP binding and obsolete signal transducer activity

	GNAS: Promotes cancer progression in hepatocellular carcinoma [115]	
GNAS-AS1:TSS-DMR	M	20	Chr20:57425979–57427973	60	GNASAS; GNAS	As above	As above	
GNAS-XL:Ex1-DMR	M	20	Chr20:57429858–57431303	5	GNAS	As above		
GNAS A/B:TSS-DMR	M	20	Chr20:57463265–57465175	40	GNAS	As above	As above	
WRB:alt-TSS-DMR	M	21	Chr21:40757691–40758208	4	WRB	Peroxisomal lipid metabolism	–	
SNU13:alt-TSS-DMR	M	22	Chr22:42077939–42078723	8	NHP2L1	Pre-mRNA splicing	Promotes cell proliferation in triple negative breast cancer [116]	
DMRs differentially methylated regions, M: maternal, P: paternal, chr: chromosome

To identify the regions with aberrant methylation pattern in NB, a probe-wise investigation was performed across the imprinted DMR. At a probe, NB cases were considered to have undergone gain of methylation (GOM) or loss of methylation (LOM) if the probe methylation level was above or below 0.8/0.2 and were classified as “GOM” and “LOM”, respectively. Moderate methylation events were also calculated by comparing beta-values of NB tumours to the probe mean of control samples. NB cases with probe methylation level below the healthy controls’ mean 2 standard deviation (SD) CI were classified as “Intermediate LOM” and those above 2 SDs CI were classified as “Intermediate GOM” [31]. Cases that did not meet the above criteria were grouped as “No change”, suggesting a normal methylation pattern. Since the imprinted DMRs were associated with more than one CpG probe, to get a region-wise indication of methylation alteration, the NB samples were further grouped based on the event that was supported by more than 60% of probes in that region. We defined the most altered regions as the regions that displayed alteration, either GOM or LOM in > 30% of NB samples in both discovery and the validation set.

Allele-specific copy number alteration profiles

The allele-specific CNA profiles were derived using ASCAT [32]. Briefly, this algorithm takes total signal intensity (Log R) and allelic contrast represented by B allele frequency (BAF) from tumour and matched germline as input. As the first step, the germline data was used to determine the germline homozygous SNP array probes. The data was then segmented using ASPCF segmentation algorithm and an “ASCAT profile” was calculated across all assayed loci. The output ASCAT profile was reported as “nMajor”, “nMinor” and “ploidy” that referred to the number of major alleles, number of minor alleles and the total copy number in specific regions, respectively, which was the key output for our analysis and allowed for an accurate derivation of gains, losses, copy-number-neutral events, and loss of heterozygosity for all the samples.

Predicted methylation analysis

CNAs that overlapped with the imprinted DMRs were investigated in this study. Prediction of methylation levels based on allele-specific CNAs was done as described [31] and was based on the following assumptions (a) if no epimutations have occurred, then methylation beta-values will be completely guided by the copy number and parental origin, in a normal diploid cell (2n), methylation will be ~ 50% (one methylated and one unmethylated allele) whereas in a cell with aneuploidy, for example 4n, the beta-values will be in a ratio of 75:25 or 25:75%, depending on the parental origin of the minor allele and (b) in all cases of copy number neutral loss of heterozygosity, beta-values will be close to zero or 1 irrespective of the total chromosome number.

Firstly, “minor methylation value” were calculated as the ratio of minor allele count and total allele count for each sample across each region. We then checked the HM450K methylation beta-value for the corresponding region. For each region, if the HM450K methylation beta-value for majority of the probes was below 0.5 or equal to 0.5, minor allele was assumed to be the methylated allele and the CNA-based predicted methylation value was reported as equal to the minor methylation value (ratio of minor allele count and total allele count). If the corresponding HM450K value was above 0.5, major allele was assumed to be the methylated allele and the CNA-based predicted methylation value was reported as 1-minor methylation value. Next, to know what proportion of methylation alterations can be explained by the underlying CNAs, a linear regression analysis was performed with observed array-based (HM450K) methylation value as outcome and CNA-based predicted methylation as predictor. A coefficient of determination (adjusted R2) was obtained for each region based on the linear regression analysis that explain the degree to which the predictor variable (CNA-based predicted methylation) explains the variation of the output variable (array-based methylation value). The value of adjusted R2 ranges from 0 to 1, where 0 indicates that the outcome cannot be explained by the predictor variable and 1 indicates vice versa. A negative adjusted R2 suggests that the model is a poor fit to the data.

Gene expression analysis

Kaplan–Meier analysis with calculation of log rank test for overall survival probability for NB in relation to the expression levels of genes, which were overlapping the seven DMRs that showed significant association with overall survival in this study were performed using the Kaplan scan cutoff method in ‘R2: Genomic Analysis and Visualization Platform’ (http://r2.amc.nl). The prognostic significance on overall survival of the DMRs were investigated using the three publicly available datasets; “Tumor Neuroblastoma SEQC-498 custom—GSE49710 (n = 498), “Tumor Neuroblastoma Maris 101 custom”—GSE3960 (n = 101) and, “Tumor Neuroblastoma Kocak 649 custom—GSE45547 (n = 649). The Kaplan scan cutoff method examines every increasing expression value as cutoff for log rank test in order to find the optimal segregation point of two groups based on gene expression. This method then presents the most statistically significant cutoff with corresponding Bonferroni corrected P-value together with the initial non-corrected P-value.

Survival analysis

Survival information was available for all 185 patients from the TARGET dataset and 68/85 (80%) samples from the validation cohort. Follow-up started at the date of diagnosis and ended at the date of death or end of follow-up, whichever came first. Methylation alterations at all 49 imprinted regions and its role in disease prognosis were tested. We compared the overall survival probability of the imprinting methylation groups in samples from the TARGET dataset with matching survival information using log-rank test. Survival analyses were undertaken using the R package Survival [33]. P-value < 0.05 was considered significant. Cox proportional hazards regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CI) for the association between methylation alterations at the imprinted DMRs and risk of death. Multivariate model with adjustment for MYCN amplification, 11q deletion and age at diagnosis were fitted.

Statistical analysis

Pearson’s Chi-squared tests were performed to assess the association between methylation changes at the imprinted regions that were most altered (i.e. underwent LOM or GOM in > 30% of samples) and clinical and molecular features of the patients/tumours. The P-values were adjusted for multiple hypotheses testing using Benjamini-Hochberg (BH) method. P-value < 0.05 was considered significant.

Results

Study participants

The samples included in this study were obtained from the TARGET (n = 185) and German Neuroblastoma Trial (n = 99), merged as discovery set and a local cohort of NB tumours (n = 85), used as validation set.

Imprinting aberrations in neuroblastoma

To study imprinting deregulation in NB, 704 CpG positions overlapping 49 imprinted DMRs as previously reported by Mora et al. (2018) [30] were investigated in the discovery set (n = 284). The details of the imprinted regions, genomic location, overlapping genes and their function is presented in Table 2. Imprinted DMRs were present in all chromosomes except chromosome 3, 12, 17 and 18. Most of the DMRs were associated with at least 2 CpG sites. Out of 704 CpG sites, 672 (95%) sites mapped to a gene (Table 2). The CpG sites were mainly located in the promoter associated regions including transcription start site 1500 (TSS1500) (37%), 5’ untranslated region (5’UTR) (21%), TSS200 (13%), 3’UTR (10%) and 1st exon (8%). Twelve percent of the CpG sites were in the gene body region.

To identify regions with altered methylation patterns, a probe-wise investigation was performed, and the samples were assigned to groups; gain of methylation (GOM) and loss of methylation (LOM), when the probe-wise methylation level was above 0.8 and below 0.2, respectively. We also defined groups with moderate changes in the methylation, namely “Intermediate GOM” and “Intermediate LOM”, based on if the methylation level of a NB sample was above or below 2 SD of the mean of the healthy control’s (healthy foetal adrenal tissue). Samples that did not meet any of the above criteria were grouped as “No change”, i.e. no methylation aberrations were observed.

Imprinted DMRs are methylated at either the maternal or paternal allele and therefore average methylation in these regions in a normal state is expected to be ~ 0.5. In all DMRs, the average methylation beta-value in the control samples (n = 11) ranged, as expected, between 0.4 and 0.6 except for four regions (GPR1, MKRN3, NNAT/BLCAP and IGF2:alt-TSS-DMR) where the average methylation of control adrenal samples was higher than 0.7. Similarly, five regions had methylation values of < 0.4 in control adrenal samples (IGF2:Ex9-DMR, IGF2R, MIR886, SNRPN:Int1-DMR1 and SVOPL) (Supplementary Table 1). However, since imprinting patterns are tissue specific, selecting the most suitable control for such analysis is challenging. Considering that NB originates from neural crest cells, foetal adrenal gland tissue may not be a suitable control for this analysis, and therefore we chose not to remove regions or disregard the results based on the methylation value of the adrenal control tissue. In our analysis strategy, we used the control group to define the moderate methylation changes, while the more stronger methylation changes defined as GOM and LOM are based on the probe-wise absolute beta-value of the NB samples. The most altered regions are also reported based on the stronger methylation changes. A heatmap displaying the beta-value of NB samples in the discovery set (n = 284), control adrenal samples (n = 11) and mUPD (n = 1) and pUPD (n = 2) samples are presented in Supplementary Fig. 1.

At least one of the NB samples displayed methylation changes in any of the 49 DMRs and no region was unaffected (Fig. 1). LOM was more commonly observed in NB samples than GOM. The top five regions where LOM was frequently observed were NDN (50% LOM, 26% Intermediate LOM), SNRPN:Int1-DMR2 (50% LOM) and MAGEL2 (37% LOM, 28% Intermediate LOM) located on chromosome 15, IGF2:Ex9-DMR (41% LOM) located at chromosome 11p, and HTR5A (34% LOM, 21% Intermediate LOM) located at chromosome 7q (Supplementary Table 1). Methylation alterations in these regions were unidirectional i.e. no NB sample underwent GOM at any of these sites, and there were only four cases of Intermediate GOM. Interestingly, six of these top ten regions with LOM events were located on chromosome 15.Fig. 1 Methylation pattern of Neuroblastoma (NB) tumour samples. Heatmap shows the methylation patterns of neuroblastoma (NB) tumour samples in the discovery set (n = 284) that included samples from Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and German Neuroblastoma Trial, across 49 imprinted differentially methylated regions (DMRs). Annotation of Imprinted DMRs by genomic position and location in the context of chromosome are marked on the heatmap. Methylation changes, namely gain of methylation (GOM), loss of methylation (LOM), Intermediate GOM, Intermediate LOM and No change identified in the analysis are shown in the heatmap as indicated in the colour key

As stated, GOM was less commonly observed in the NB samples but did occur. The region with the highest frequency (75%) of GOM was NNAT/BLCAP located at chromosome 20q. Other regions with GOM were RB1 (46%) located on 13q, GPR1 (33%) located on 2q, MIR886 (25%) located on 5q, PPIEL:Ex1-DMR (18% GOM, 17% Intermediate GOM) located on 1p and WDR27 (15% GOM, 18% Intermediate GOM) located on 6q (Fig. 1). In contrast, there were some regions that were largely unaffected by any methylation events. These included GNAS-AS1:TSS-DMR, ZIM2/PEG3/MIMT1, H19/MIR675, MEG3 and ZNF331:alt-TSS-DMR1, where more than 90% of the NB samples had unaltered methylation levels.

Replication in local cohort

The results from the methylation analysis were validated in a local cohort of 85 NB samples. Methylation profiles of NB samples at the imprinted DMRs had a similar pattern in the validation set (Fig. 2). Consistent with the discovery set, LOM was prominently observed at DMRs on chromosome 15. Regions where LOM was observed frequently (> 30% of the NB samples) in the discovery set also ranked highly in the validation set. Regions with frequent GOM events (> 30% of the NB samples) remained consistent in the validation set (Fig. 2). Methylation alterations at the imprinted DMRs in NB tumours from the three datasets; TARGET, German Neuroblastoma Trial, and the local cohort is presented in individual heatmaps (Supplementary Fig. 2A–C) and sample proportions in the individual datasets in Supplementary Table 2.Fig. 2 Methylation alterations in the validation set. Stacked barplots present a comparison of the methylation patterns of neuroblastoma (NB) samples in the discovery set (n = 284) and the validation set (n = 85). Methylation changes displayed by the NB tumours that included gain of methylation (GOM), loss of methylation (LOM), Intermediate GOM, Intermediate LOM or No change at the imprinted differentially methylated regions (DMRs) are presented as indicated in the colour key. The imprinted regions are ordered by proportion of samples displaying LOM and GOM in the public dataset with the regions displaying the most alterations in the public dataset shown on the top

Association with tumour features and established molecular groups

After identifying the imprinted DMRs with the most altered methylation, we next investigated whether the identified methylation changes in these regions were associated with clinical or genomic features of the tumours. Pearson’s Chi-squared tests were performed to assess the association between methylation changes at the imprinted regions that were most altered (i.e. underwent LOM or GOM in > 30% of samples) and tumour characteristics including age group at diagnosis, tumour stage, 11q deletion or MYCN amplification status. Association with methylation-based subclasses as defined by the molecular neuropathology classifier were also assessed [34]. Since the discovery set and the validation set displayed largely similar methylation pattern at the imprinted regions, the two sets were combined to increase the sample size and the power of the correlation tests.

Significant associations between methylation alterations at the imprinted DMRs and clinical and genomic features were observed (Supplementary Table 3). Change in methylation levels for example at RB1 (BH adjusted P = 8.5e-17), NNAT/BLCAP (BH adjusted P = 3.5e-16) and MAGEL2 (BH adjusted P = 2.0e-15) correlated strongly with higher age at diagnosis. Tumours that underwent methylation changes at these regions were diagnosed at an older age (> 1.5 years) compared to the tumours that had unaltered methylation patterns at these sites (Fig. 3A). A significant difference in the total number of imprinted DMRs that underwent methylation changes was also observed between group of patients with age at diagnosis above and below 1.5 years. Patients with older age at diagnosis (above 1.5 years) had significantly larger number of regions that underwent LOM (P = 3.5e-12) and GOM (P = 2.4e-18) when compared with patients that were below 1.5 years at diagnosis (Fig. 3A). Methylation changes in these regions also correlated with stage 4 tumours. For cases that displayed GOM at RB1 and NNAT/BLCAP, 85% and 80%, respectively were classified as stage 4 tumours, although we also see stage 4 tumour cases (41%) in the “No change” group at RB1. Loss of methylation at MAGEL2 was predominantly associated with stage 4 tumours (87% of cases in LOM group and 63% of cases in the Intermediate LOM group) (Fig. 3B). Comparing the total number of imprinted DMRs undergoing methylation changes between the different tumour stages, we found that in comparison with stage 1 tumours, stage 4 and stage 3 tumour cases had significantly larger number of imprinted DMRs undergoing LOM (stage 4 vs stage 1, BH adjusted P = 3.2e-05, stage 3 vs stage 1, BH adjusted P = 0.0001) and GOM (stage 4 vs stage 1, BH adjusted P = 6.4e-09, stage 3 vs stage 1, BH adjusted P = 1.3e-04) (Fig. 3B). On the other hand, methylation changes at imprinted regions were relatively less frequent in stage 4 s tumours. In comparison with stage 4 and stage 3 tumours, stage 4 s tumour cases had significantly fewer number of imprinted DMRs undergoing LOM (stage 4 vs stage 4 s, BH adjusted P = 2.4e-12 and stage 3 vs stage 4 s, BH adjusted P = 2.2e-05) and GOM (stage 4 vs stage 4 s, BH adjusted P = 1.9e-11 and stage 3 vs stage 4 s, BH adjusted P = 3.0e-04) (Fig. 3B).Fig. 3 Methylation alterations at the imprinted regions and association with clinical and genomic features. Bar plots show the frequency of 369 NB samples in a combined cohort of the discovery set and the validation set grouped based on A age at diagnosis B tumour stage C MYCN amplification D 11q deletion and E Molecular subclasses (defined based on the molecular neuropathology classifier), stratified by methylation alterations at the imprinted differentially methylated regions (DMRs) namely, gain of methylation (GOM), loss of methylation (LOM), Intermediate LOM (IL), Intermediate GOM (IG) and No change. Box plots on the right panel show the difference in the total number of imprinted DMRs undergoing methylation changes (GOM or LOM) between the NB tumours in different clinical groups mentioned above. P-values were corrected for multiple hypotheses testing using Benjamini–Hochberg method

Methylation alterations at RB1, NNAT/BLCAP and MAGEL2 also correlated significantly with amplification of MYCN. Of the cases that displayed GOM at RB1 and NNAT/BLCAP, 50% and 38%, respectively, had amplification of MYCN, whereas of the cases with no change in methylation at these regions only 11% and 5%, respectively, had amplification of MYCN. At MAGEL2, 46% of cases with LOM and 12% of cases with Intermediate LOM had amplification of MYCN (Fig. 3C). MYCN-amplified NB cases also had significantly larger number of DMRs that displayed LOM (P = 4.7e-07) and GOM (P = 5.e-14) compared to the cases with no amplification of MYCN (Fig. 3C). In case of 11q deletion, methylation changes at NDN and NNAT/BLCAP correlated strongly with 11q deletion. Of the cases that displayed LOM at NDN and GOM at NNAT/BLCAP, 31% and 38%, respectively, had deletion of 11q, whereas of the cases with no change in methylation at these regions 23% and 16%, respectively, had deletion of 11q. At RB1 on the other hand, the majority of cases that displayed GOM had normal 11q (71%) (Fig. 3D). In terms of total number of imprinted DMRs that underwent methylation changes, no significant difference was observed between the cases that had 11q deletion and the cases that had normal copy of the 11q chromosome. However, tumour cases that had a loss of the whole chromosome 11 harboured significantly lower number of imprinted DMRs undergoing methylation changes in comparison to both 11q-deleted (LOM: BH adjusted P = 2.5e-10, GOM, BH adjusted P = 1.9e-05) and 11q-normal (LOM: BH adjusted P = 3.3e-10, GOM, BH adjusted P = 1.9e-05) cases (Fig. 3D).

DNA methylation-based classification is successfully used for central nervous system tumour classification [34–36]. In the current Molecular Neuropathology (MNP) classifier, NB can be classified into three methylation subclasses namely Alt/Tert Tmm Positive, Mycn Type and Tmm Negative. Atl/Tert Tmm Positive molecular subclass includes the NB tumours that show an activation of the telomerase maintenance mechanism (Tmm) and is associated with a poor outcome. On the other hand, the Tmm Negative NB tumours lack this mechanism and thus have better prognosis [37]. The Mycn Type, as the name suggests, includes tumours that harbor amplification of the MYCN gene. In the combined dataset (discovery and validation), 37% of NB tumours were classified as Mycn Type, 27% as Alt/Tert Tmm Positive and 30% as Tmm Negative. There were 21 cases that remained unclassified due to subclassification score < 0.5 and were subsequently excluded from the assessment in the correlation between methylation-based subclasses and the imprinting groups at the imprinted DMRs.

Methylation alterations (GOM or LOM) at NNAT/BLCAP (BH adjusted P = 2.0e-08), RB1 (BH adjusted P = 2.4e-14) and MAGEL2 (BH adjusted P = 5.3e-08) showed an enrichment for the methylation subclass Mycn Type. Interestingly, most of the tumours that retained their methylation profile (No change group) at these DMRs were classified as Tmm negative (76% of cases with no change at NNAT/BLCAP, 55% at RB and 53% at MAGEL2) (Fig. 3E). The tumours, however, that harboured methylation alterations at these regions were mainly classified as Mycn Type. At RB1, 68% cases that underwent GOM were classified as Mycn Type, 26% as Alt/Tert Tmm Positive and 6% as Tmm Negative. Similarly at NNAT/BLCAP, 49% cases that underwent GOM were classified as Mycn Type, 35% as Alt/Tert Tmm Positive and 16% as Tmm Negative. At MAGEL2, 60% cases with LOM were classified as Mycn Type, 34% as Alt/Tert Tmm Positive and 5% as Tmm Negative. The difference was also evident when we compared the total number of DMRs that underwent methylation changes between the molecular subclasses. Tmm negative had significantly fewer DMRs that were affected by methylation changes (LOM or GOM) when compared with Alt/Tert Tmm Positive (LOM, BH adjusted P = 1.1e-07 and GOM, BH adjusted P = 2.5e-15) and Mycn Type (LOM, BH adjusted P = 1.6e-20 and GOM, BH adjusted P = 1.4e-33) subclasses (Fig. 3E). The MYCN Type group had the largest number of imprinted regions affected by methylation changes among the molecular subclasses (Fig. 3E).

Methylation changes at imprinted DMRs and association with overall survival

To compare risk prediction of the DMRs we combined the survival data and the imprinting groups from the public (TARGET) and the local cohort. Survival data was not available for the German Neuroblastoma study. The pooled analysis indicated that methylation alteration was associated with overall survival for six DMRs. A loss in methylation at MAGEL2 (P = 0.0001) and MKRN3 (P = 0.04) was significantly associated with poorer overall survival. Methylation gains were associated significantly with shorter overall survival for MIR886 (P = 0.0001), RB1 (P = 0.005), NNAT/BLCAP (P = 8.1e-05) and INPP5F (P = 0.01) (Fig. 4A). Kaplan–Meier plots showing the risk prediction of DMRs in TARGET and the local cohort separately is presented in the Supplementary Fig. 3A and 3B, respectively.Fig. 4 Overall survival probability. A Kaplan–Meier plots show the differences in overall survival probability of 253 neuroblastoma (NB) patients in the pooled cohort of samples in the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) dataset and local cohort, stratified by methylation alterations at the imprinted differentially methylated regions (DMRs), which are gain of methylation (GOM), loss of methylation (LOM), Intermediate LOM, Intermediate GOM and No change. B Kaplan–Meier plots show the differences in overall survival probability of MYCN non-amplified NB patients stratified by methylation alterations at the imprinted DMRs and 11q deletion. Dotted line in the plots represents MYCN non-amplified NB tumours with a deletion of 11q while the solid line represents tumours that were MYCN non-amplified with a normal copy of 11q

To further examine the prognostic significance of the imprinted DMRs in low-risk NB group, i.e. the cases that were MYCN non-amplified and 11q-normal (no amplification of MYCN and no deletion of 11q), we compared their survival probabilities and found that the imprinted DMRs were able to further stratify MYCN non-amplified and 11q-normal NB cases. MYCN non-amplified and 11q-normal cases that underwent GOM had a shorter overall survival rate compared to the MYCN non-amplified and 11q-normal cases with no methylation alterations at RB1 (P = 0.02) and NNAT/BLACP (P = 0.02) (Fig. 4B). Similarly, at MKRN3, MYCN non-amplified and 11q-normal that underwent LOM had shorter survival probability compared to the MYCN non-amplified and 11q-normal cases that did not have any methylation changes at this site (P = 0.03). Although the difference was not statistically significant at MAGEL2 and MIR886, we see a similar trend with MYCN non-amplified and 11q-normal cases undergoing LOM or Intermediate LOM having shorter overall survival probability (P = 0.06). At all these DMRs, the cases that had 11q-deletion and that also underwent methylation changes had the poorest survival rate (Fig. 4B).

MYCN amplification, 11q deletion and age at diagnosis are established prognostic biomarkers used for risk stratification in NB. To determine the contribution of the imprinted DMRs, we performed a multivariate analysis using cox proportional hazards regression model and compared the risk prediction of imprinted DMRs (MIR886, RB1, NNAT/BLCAP, MAGEL2, MKRN3, and INPP5F) after adjusting for MYCN amplification, 11q deletion and age at diagnosis. MYCN amplification status was not known for one case in the local cohort and 11q deletion status was not known for two cases in TARGET and were removed from further analysis.

Table 3 presents the hazard ratios (HRs) of the imprinted DMRs and the established risk factors (age at diagnosis, MYCN amplification and 11q deletion) as a comparison. The HRs for all the six DMRs were positive indicating an increase in hazard with methylation changes at these regions. Strongest evidence of association was observed for NNAT/BLCAP [GOM vs No change, HR (95% CI) = 3.0 (1.7–5.3), P < 0.001], MAGEL2 [LOM vs No change HR (95% CI) = 2.6 (1.5–4.4), P < 0.001], RB1 [GOM vs No change, HR (95% CI) = 1.7 (1.2–2.4), P = 0.005] and MIR886 [GOM vs No change, HR (95% CI) = 2.1 (1.4–3.0), P < 0.001]. After adjusting for age at diagnosis and MYCN amplification, the association remained consistent for NNAT/BLCAP [GOM vs No change, HR (95% CI) = 2.0 (1.1–3.7), P = 0.03] and MAGEL2 [LOM vs No change HR (95% CI) = 2.1 (1.2–3.7), P = 0.01]. Weak evidence of association was also observed for MIR886 [GOM vs No change, HR (95% CI) = 1.5 (1.0–2.3), P = 0.05] (Fig. 5A). After adjusting for age at diagnosis and 11q deletion, methylation alterations at NNAT/BLCAP [GOM vs No change, HR (95% CI) = 2.2 (1.2–4.0), P = 0.01], MAGEL2 [LOM vs No change, HR (95% CI) = 2.1 (1.2–3.7), P = 0.01] and MIR886 [GOM vs No change, HR (95% CI) = 1.7 (1.1–2.4), P = 0.01] were found to be associated with an increase in hazard (Fig. 5B).Table 3 Hazard ratios (HRs) in the pooled cohort of samples from Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and the local cohort

Risk of death	HR	Lower 95%	Upper 95%	P-value	
Age at diagnosis: Above 1.5 years (n = 190)	3.4	1.9	6.1	< 0.001	
MYCN amplification: MYCN amplified (n = 70)	2.0	1.4	2.9	< 0.001	
11q deletion: 11q deleted (n = 82)	1.4	1.0	2.0	0.06	
MIR886: GOM (n = 60)	2.1	1.4	3.0	< 0.001	
RB1: GOM (n = 132)	1.7	1.2	2.4	0.005	
NNAT/BLCAP: GOM (n = 193)	3.0	1.7	5.3	< 0.001	
MAGEL2: LOM (n = 115)	2.6	1.5	4.3	< 0.001	
MKRN3: LOM (n = 21)	1.9	1.0	3.4	0.04	
INPP5F: GOM (n = 13)	2.4	1.2	4.7	0.01	
GOM gain of methylation, LOM loss of methylation

Fig. 5 Multivariate survival analysis. Cox proportional hazards regression model of overall survival of samples in the pooled cohort (Therapeutically Applicable Research to Generate Effective Treatments (TARGET) dataset and local cohort) comparing methylation alterations at NNAT/BLCAP, MAGEL2 and MIR886 and increase in hazard after adjusting for A age at diagnosis and MYCN amplification and B age at diagnosis and 11q deletion

Expression of the identified imprinted genes separates patients into risk groups

To check if the imprinted DMRs can stratify patients into risk groups based on data from gene expression arrays, we looked at the genes mapping to the identified DMRs in three datasets (Maris n = 101, Kocak n = 649 and SEQC n = 498) with gene expression data in the R2 database (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi?species=hs). The prognostic significance of the genes mapping to all six DMRs identified above were tested, including NNAT, RB1, MAGEL2, MKRN3 and INPP5F. Gene expression data was not available for MIR886.

For MKRN3, that underwent LOM, a higher gene expression level (theoretically related to a loss in methylation) was found to be associated with poorer overall survival across the three datasets. Whereas for NNAT, RB1 and INPP5F, regions that underwent GOM, lower gene expression levels (theoretically related to a gain in methylation) was associated with poorer overall survival. However, at MAGEL2, risk stratification based on DNA methylation and gene expression data did not show an expected correlation. Kaplan–Meier plots showing the risk prediction of DMRs based on the gene expression data in the SEQC dataset is presented in Fig. 6.Fig. 6 Risk prediction based on gene expression levels. Kaplan–Meier plots generated using the Kaplan scan cutoff method in ‘R2: Genomic Analysis and Visualization Platform’ (http://r2.amc.nl) show the differences in overall survival probabilities in 498 neuroblastoma (NB) samples from publicly available dataset SEQC-498 custom (GSE49710), stratified by gene expression levels of the genes overlapping the imprinted regions

Association between DNA methylation and allele-specific CNAs

Chromosomal alterations including whole chromosome gain or loss as well as segmental chromosomal alterations are commonly seen in NB tumours. Gain or loss of a chromosomal segment including or in the vicinity of an imprinted region could also lead to imprinting aberrations. Since data from the methylation arrays are not allele-specific, the deviation from the mono-allelic methylation pattern at the imprinted regions could be both due to epigenetic changes and CNAs, which cannot be distinguished based on only the methylation array data. For instance, both loss of methylation at the methylated allele or a loss of copy number of the methylated allele will result in a low beta-value suggesting a loss of methylation and thus an upregulation in gene expression. However, in reality, in the first situation, there will be an upregulation of gene expression while in the second case the gene expression remains the same as the unmethylated copy remains intact.

So, to understand the relation between CNAs and the observed array-based DNA methylation levels at the imprinted regions, we investigated the allele-specific CNA data (derived using ASCAT from SNP-array data) available for 105 out of the 185 samples included in the TARGET dataset. We combined the allele-specific CNA data and DNA methylation levels at genomic locations mapping to the imprinted DMRs. CNA information was not available for the imprinted region FANCC, located on 9q and it was therefore removed from further analysis. Out of 105 NB cases, only three had normal copy number at all imprinted regions, the remaining samples either had a gain or loss of copy number in at least one of the imprinted regions. Fifteen out of 105 (14%) cases had copy number gain (total copy number > 2) in all imprinted DMRs with the most affected regions being SVOPL (Chr7:138348774–138348981), HTR5A (Chr7:154862770–154863381), MESTIT1/MEST (Chr7:130130122–130133110), SGCE/PEG10 (Chr7:94285642–94287242), GRB10 (Chr7:50849168–50850870) and PPIEL:Ex1-DMR (Chr1:40024971–40025415).

To further understand the relationship between CNAs and DNA methylation, a prediction of methylation levels based on the allele-specific CNAs was done (as described in the method section). We performed a linear regression analysis with array-based methylation levels as outcome and CNA-based predicted methylation value as predictor. CNAs explained over 50% of the methylation variations observed across several imprinted DMRs (Table 4). Higher adjusted r-squared suggests a higher proportion of observed methylation changes explained by CNAs. However, we found that the regions that had the most altered methylation patterns were not dictated by the underlying CNAs suggesting true epimutations including the regions that underwent most LOM: NDN (adjusted R2 = − 0.002), MAGEL2 (adjusted R2 = − 0.005), HTR5A (adjusted R2 = − 0.009), SNRPN:Int1-DMR2 (adjusted R2 = − 0.006) and IGF2:Ex9-DMR (adjusted R2 = − 0.009) and the regions that underwent most GOM: NNAT/BLCAP (adjusted R2 = 0.002), RB1 (adjusted R2 = − 0.005) and GPR1 (adjusted R2 = 0.05). For many of these regions the value of adjusted R2 was negative indicating that CNAs were not at all a good predictor variable for the observed methylation changes in these regions. Regression plots demonstrating the correlation between observed (HM450K) and CNA-based predicted methylation values for NDN, MAGEL2 (where no correlation was observed) and for regions where strong correlation was observed as a contrast is presented in Fig. 7A and B, respectively.Table 4 Proportion of methylation variance explained by copy-number alterations

Imprinted DMRs	Adjusted R2	P-value	
KCNQ1OT1:TSS-DMR	0.73532217	2.01E-31	
DIRAS3:TSS-DMR	0.72717398	4.94E-31	
PPIEL:Ex1-DMR	0.72629062	5.83E-31	
GNAS A/B:TSS-DMR	0.68381104	1.81E-27	
INPP5F:Int2-DMR	0.67455518	7.93E-27	
GNAS-NESP:TSS-DMR	0.65934637	8.24E-26	
GNAS-XL:Ex1-DMR	0.63036721	5.41E-24	
DIRAS3:Ex2-DMR	0.61564651	2.47E-23	
L3MBTL1:alt-TSS-DMR	0.58608032	1.80E-21	
MEG3:TSS-DMR	0.55847104	1.13E-19	
PLAGL1:alt-TSS-DMR	0.55002662	8.76E-20	
PEG10:TSS-DMR	0.54929279	9.53E-20	
PEG13:TSS-DMR	0.54917723	9.66E-20	
ZNF331:alt-TSS-DMR2	0.53461125	7.41E-19	
MEST:alt-TSS-DMR	0.51018985	7.16E-18	
GNAS-AS1:TSS-DMR	0.49100914	7.43E-17	
WRB:alt-TSS-DMR	0.42274926	8.54E-14	
MCTS2P:TSS-DMR	0.42075918	5.83E-14	
ZNF331:alt-TSS-DMR1	0.41756253	7.75E-14	
PEG3:TSS-DMR	0.41421214	1.04E-13	
SNU13:alt-TSS-DMR	0.35982975	8.20E-12	
IGF2:alt-TSS-DMR	0.33361469	8.26E-11	
IGF1R:Int2-DMR	0.29620759	1.41E-09	
WDR27:Int13-DMR	0.25058316	3.23E-08	
H19/IGF2:IG-DMR	0.24516293	5.47E-08	
MEG8:Int2-DMR	0.2296524	2.08E-07	
FAM50B:TSS-DMR	0.2196904	2.75E-07	
VTRNA2-1:DMR	0.17697779	4.70E-06	
IGF2R:Int2-DMR	0.16691076	9.01E-06	
ZDBF2/GPR1:IG-DMR	0.16528803	1.00E-05	
SNURF:TSS-DMR	0.16486644	1.13E-05	
ERLIN2:Int6-DMR	0.14249812	4.27E-05	
MKRN3:TSS-DMR	0.12079245	1.77E-04	
GRB10:alt-TSS-DMR	0.0975089	6.93E-04	
SNRPN:alt-TSS-DMR	0.07896148	2.24E-03	
ZNF597:TSS-DMR	0.05618441	9.11E-03	
GPR1-AS:TSS-DMR	0.05523454	9.04E-03	
NAP1L5:TSS-DMR	0.05124134	1.26E-02	
SVOPL:alt-TSS-DMR	0.03792309	2.60E-02	
ZNF597:3' DMR	0.03056095	4.26E-02	
SNRPN:Int1-DMR1	0.01495803	1.12E-01	
NNAT:TSS-DMR	0.00195492	2.76E-01	
NDN:TSS-DMR	− 0.00200942	3.75E-01	
RB1:Int2-DMR	− 0.00497893	4.88E-01	
MAGEL2:TSS-DMR	− 0.0051687	4.94E-01	
SNRPN:Int1-DMR2	− 0.00613663	5.43E-01	
IGF2:Ex9-DMR	− 0.00891498	7.65E-01	
HTR5A:TSS-DMR	− 0.0095237	8.91E-01	
DMR Differentially methylated region. P-values are for the linear regression analysis

Adjusted R2 are from the linear regression model

Fig. 7 Analysis of copy number alterations and methylation at the imprinted regions. The observed (Illumina Human Methylation 450 k array-based methylation levels) versus expected (copy number alterations (CNAs) based predicted methylation levels) methylation profile of 105 neuroblastoma (NB) tumours in Therapeutically Applicable Research to Generate Effective Treatments (TARGET) dataset at A imprinted regions where CNAs were not able to predict the methylation profile as observed based on the methylation array and B imprinted DMRs where CNAs were able to predict the methylation profile of NB tumours as observed based on the methylation array. The dashed lines represent the ± 2 standard deviation (SD) of the mean of normal adrenal control tissues. Colours of the data points represent the methylation alteration that the NB tumours display at the imprinted region, which are gain of methylation (GOM) or loss of methylation (LOM), if the absolute beta-value of the NB tumour is above 0.8 or below 0.2, respectively and Intermediate GOM or Intermediate LOM, if the methylation level of NB sample is above or below the healthy controls’ mean 2 SD, respectively. Shape of the data points represent total ploidy of the NB tumours at the imprinted regions. P-value < 0.05 represents significant correlation between the two variables

Discussion

Using publicly available clinical and DNA methylation data from TARGET and German Neuroblastoma Trial study, and a Swedish cohort of samples, the methylation profiles of totally 369 NB samples in 49 imprinted DMRs were investigated with the aim of identifying regions that were most altered in NB tumours. We demonstrated that loss in methylation was a more common occurrence compared to a gain in methylation event in NB tumours at the imprinted regions. Key genes overlapping the most altered regions were NDN, SNRPN, MAGEL2, HTR5A, IGF2 and INS-IGF2 (LOM in > 30% of NB samples) and NNAT, BLCAP, RB1, GPR1 (GOM in > 30% of NB samples). These regions remained consistent in the validation set, particularly the regions that displayed the most frequent alterations. Many of these genes have previously been reported in cancer and also in the context of NB including NNAT, RB1, MAGEL2, GPR1, NDN [38–41]. NDN, where LOM was observed in 50% and intermediate LOM in 26% of NB samples, is involved in permanent growth arrest in post-mitotic neurons during the nervous system development [42] and is downregulated in several cancers [40, 41, 43]. Studies show that NDN functionally interacts with the p53 protein [44, 45] and have an antagonistic effect on p53-mediated apoptosis [44]. LOI of the IGF2 locus has been implicated in other malignancies. Here we found that IGF2:Ex9-DMR, overlapping IGF2 and INS-IGF2 genes, displayed LOM in 41% of NB samples. MAGEL2, where 37% NB tumours displayed LOM and 28% Intermediate LOM, belongs to a highly conserved group of proteins (MAGE-The Melanoma Antigen Gene), which are reported to be deregulated in multiple cancers [46–48] including central nervous system tumours medulloblastoma [49] and glioblastoma [50]. NNAT that underwent GOM in a larger proportion of NB tumours (75%) is involved in mammalian brain development and has previously been reported in NB as a potential tumour suppressor [38]. High expression levels of NNAT have been found to be associated with good prognosis [38]. A recent study reported the involvement of NNAT with oxidative stress in ER + breast cancer [51]. This is an interesting link as oxidative stress is also reported in NB [52] and it may be related to the deregulation in NNAT gene expression. RB1 overlapping with the imprinted region RB1:Int2-DMR, where 46% of NB tumours displayed GOM in our study, has also previously been reported as an independent prognostic biomarker for NB where low RB1 expression correlated with poor prognosis [39]. Our data also illustrated that several of the most altered regions in NB showed correlations with aggressive tumour behavior that included older age at diagnosis, higher stage tumour and amplification of MYCN. The strongest correlation was observed for NNAT/BLACP and RB1 and MAGEL2 and the tumours that underwent methylation alterations at these regions were > 1.5 years of age, had stage 4 tumour and were MYCN amplified. A correlation between the total number of imprinted DMRs undergoing methylation changes and clinical behaviour was also observed (Fig. 3). Patients that accumulated methylation changes in a larger number of imprinted regions were diagnosed at an older age (above 1.5 years), with more advanced tumour (stage 3 and stage 4) and with an amplification of MYCN. Interestingly, NB cases with 11q deletion did not differ significantly in terms of number of imprinted regions undergoing methylation changes with the cases that had no alteration at 11q. On the other hand, cases that had loss of whole chromosome 11 had significantly lesser number of imprinted regions with methylation alterations. This is consistent with previous reports where loss of whole chromosomes were found to be associated with less aggressive clinical behaviour and better prognosis [10]. Also consistent with previous findings where TMM negative molecular subclass has been associated with better prognosis [37], we found that the NB cases in this subclass had the lowest number of imprinted regions with altered methylation patterns. In contrast, the MYCN Type had the largest number of imprinted regions with altered methylation patterns. These results suggest that alterations in methylation patterns at imprinted regions has a role in promoting tumour growth, and accumulation in terms of number is also indicative of more aggressive clinical features.

Imprinting dysregulation has been shown to be associated with tumour progression and patient survival [24]. We tested the association between methylation alterations at the 49 imprinted DMRs and overall survival probabilities of patients. Our data showed that methylation alterations at six of the 49 imprinted DMRs tested was associated with shorter overall survival (MIR886, RB1, NNAT/BLCAP, MAGEL2, MKRN3 and INPP5F). GOM at NNAT/BLCAP (P = 8.1e-05), RB1 (P = 0.005), MIR886 (P = 0.0002) and INPP5F (GOM, P = 0.01) correlated significantly with poorer overall survival. A gain of methylation (GOM) could be hypothesized to result in reduced expression of the corresponding gene. Through gene expression-based stratification of patients in the R2 database, we demonstrated that for the genes mapping to the regions i.e. NNAT, RB1 and INPP5F, that underwent GOM, a lower gene expression (related to higher DNA methylation levels) was associated with shorter survival. Gene expression-based prognostication could not be tested for MIR886 as data was not available. However, gain of methylation at this gene has previously been reported to be predictive of poor prognosis in lung cancer [53], esophageal cancer [54] and in leukemia [55]. LOM at MKRN3 (P = 0.04) and MAGEL2 (P = 0.0001) correlated significantly with poorer overall survival. We found that higher gene expression level (related to a loss of methylation) was associated with poorer overall survival for MKRN3 in the R2 database. This therefore indicated that the imprinted genes could stratify patients into risk group based on the DNA methylation levels that also relates to the gene expression levels.

Amplification of MYCN and deletion at 11q are established prognostic markers for NB with poor outcome, where MYCN amplification is present in 20–30% [56] and 11q deletion is present in 35–45% of all NB tumours [10]. These genetic events are rarely detected in a single tumour [57, 58]. Our data further demonstrated that methylation changes at RB1, NNAT/BLCAP and MKRN3 were able to more precisely and further sub-stratify MYCN non-amplified and 11q normal cases (cases lacking amplification of MYCN and 11q deletion) into risk groups, which is currently treated as one low-risk group based on the existing risk markers. Among patients lacking MYCN amplification and 11q deletion, methylation changes at these sites were significantly associated with poorer prognosis when compared with the patients with no alterations in methylation at these sites. This suggests that among the patient group without MYCN amplification and 11q deletion, currently treated as low-risk, there are sub-groups with increased risk that are missed. Our data demonstrated that cases with 11q-deletion and absence of MYCN amplification which also harbored methylation changes at RB1, NNAT/BLCAP and MKRN3 had the poorest survival probability (Fig. 4B). This suggest that incorporating methylation status of the imprinted regions with the existing risk predictors will make the prognostication more precise. This was further supported by the multivariate analysis where we compared the prognostic significance of the imprinted genes, adjusting for age at diagnosis, MYCN amplification or 11q deletion. We demonstrated that methylation alterations at NNAT/BLCAP (P = 0.03) and MAGEL2 (P = 0.01) predicted worse outcome independently of age at diagnosis and MYCN amplification. While methylation alterations at MIR886 show a slightly weaker association with increased hazard in MYCN amplified NB tumours (Fig. 5A), methylation alterations at this region were found to be strongly associated with increased hazard in NB tumours with 11q deletion (Fig. 5B).

Ribaraska et al., (2014) reported several imprinted genes with deregulated gene expression in prostate cancer but they displayed a stable DNA methylation pattern, suggesting that somatically acquired CNAs in the close vicinity of imprinted genes may also be the cause of LOI [40]. This finding was supported by another recent study that showed that methylation profiles at imprinted DMRs largely represent the accumulation of CNAs [31]. Using matching allele-specific CNAs data from the TARGET dataset, we demonstrated that the regions that displayed most alterations in methylation patterns were found to be true epigenetic changes and were not due to CNAs in their vicinity. However, CNAs do dictate the observed methylation alterations in many of the imprinted regions. One limitation of the study was that only 49 imprinting regions were investigated and there may be other imprinted regions that are deregulated in NB. In addition, some of the imprinted DMRs contained few CpG probes that may not provide a true representation of methylation pattern in those regions and thus require further validation. Further study using whole-genome bisulfite sequencing is warranted that would offer more precise allele-specific methylation patterns at the identified imprinted regions. Validating the findings across independent datasets would help address the heterogeneity of NB and ensure that the identified methylation patterns are consistent with prognosis. Understanding how these alterations affect gene expression and tumor behaviour could provide deeper insights into their potential as therapeutic targets.

Conclusions

We demonstrated that imprinting dysregulation is prevalent in NB and methylation alterations at imprinted genes may explain differences in patient prognosis and can be used as independent prognostic biomarkers. Incorporating methylation status of imprinted regions could refine current prognostication and identify further risk sub-groups within the low-risk group.

Supplementary Information

Additional file 1

Additional file 2

Abbreviations

BH Benjamini-Hochberg

CNAs Copy number alterations

CI Confidence interval

COG Children’s Oncology Group

DMRs Differentially methylated regions

GEO Gene expression omnibus

GOM Gain of methylation

HR-NB High-risk neuroblastoma

HM450K HumanMethylation450

HR Hazard ratio

INSS International neuroblastoma staging system

LOI Loss of imprinting

LOM Loss of methylation

mUPD Maternal uniparental diploidy

MNP Molecular neuropathology

NB Neuroblastoma

pUPD Paternal uniparental diploidy

SNP Single nucleotide polymorphism

SD Standard deviation

TSS1500 Transcription start site 1500

Tmm Telomerase maintenance mechanism

TARGET Therapeutically applicable research to generate effective treatments

5’UTR 5’ Untranslated region

3’UTR 3’ Untranslated region

Acknowledgements

We thank Anas K M Madi for administrative assistance.

Author contributions

MS conducted analyses and drafted the manuscript; HC and TK led the analyses and contributed to the manuscript drafting; JIY contributed in some parts of data analysis. HC conceived the study and supervised the work. SF, JS, AD, ML, TM and PK provided clinical data. All authors read and approved the final version of the manuscript.

Funding

Open access funding provided by University of Gothenburg. The study was supported by the Swedish Cancer Society, the Swedish Research Council, Wilhelm and Martina Lundgren Science Fund, Lindhés Advokatbyrå AB, Sahlgrenska University hospital and Laboratory medicine research and development grant and the Swedish Childhood Cancer Foundation.

Availability of data and materials

The results published here are in part based upon data generated by the Therapeutically Applicable Research to Generate Effective Treatments (https://www.cancer.gov/ccg/research/genome-sequencing/target) initiative, phs000218. The data used for this analysis is available at the Genomic Data Commons (https://portal.gdc.cancer.gov).” Other datasets used in the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The tumor material was collected after receiving the informed written or verbal consent from the parents/guardians according to the ethical permits approved by the local ethics committee (Karolinska Institutet and Karolinska University Hospital, registration number 03-736 and 2009/1369) in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Newman EA Abdessalam S Aldrink JH Austin M Heaton TE Bruny J Update on neuroblastoma J Pediatr Surg 2019 54 3 383 389 10.1016/j.jpedsurg.2018.09.004 30305231
Newman EA, Abdessalam S, Aldrink JH, Austin M, Heaton TE, Bruny J, et al. Update on neuroblastoma. J Pediatr Surg. 2019;54(3):383–9.30305231 10.1016/j.jpedsurg.2018.09.004
2. Pinto NR Applebaum MA Volchenboum SL Matthay KK London WB Ambros PF Advances in risk classification and treatment strategies for neuroblastoma J Clin Oncol 2015 33 27 3008 3017 10.1200/JCO.2014.59.4648 26304901
Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008–17.26304901 10.1200/JCO.2014.59.4648
3. London WB Bagatell R Weigel BJ Fox E Guo D Van Ryn C Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials Cancer 2017 123 24 4914 4923 10.1002/cncr.30934 28885700
London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 2017;123(24):4914–23.28885700 10.1002/cncr.30934
4. Carén H Abel F Kogner P Martinsson T High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours Biochem J 2008 416 2 153 159 10.1042/BJ20081834 18990089
Carén H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008;416(2):153–9.18990089 10.1042/BJ20081834
5. Janoueix-Lerosey I Lequin D Brugières L Ribeiro A De Pontual L Combaret V Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma Nature 2008 455 7215 967 970 10.1038/nature07398 18923523
Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, De Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008;455(7215):967–70.18923523 10.1038/nature07398
6. Mossé YP Laudenslager M Longo L Cole KA Wood A Attiyeh EF Identification of ALK as a major familial neuroblastoma predisposition gene Nature 2008 455 7215 930 935 10.1038/nature07261 18724359
Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455(7215):930–5.18724359 10.1038/nature07261
7. Rosswog C Fassunke J Ernst A Schömig-Markiefka B Merkelbach-Bruse S Bartenhagen C Genomic ALK alterations in primary and relapsed neuroblastoma Br J Cancer 2023 128 8 1559 1571 10.1038/s41416-023-02208-y 36807339
Rosswog C, Fassunke J, Ernst A, Schömig-Markiefka B, Merkelbach-Bruse S, Bartenhagen C, et al. Genomic ALK alterations in primary and relapsed neuroblastoma. Br J Cancer. 2023;128(8):1559–71.36807339 10.1038/s41416-023-02208-y
8. Schleiermacher G Javanmardi N Bernard V Leroy Q Cappo J Rio Frio T Emergence of new ALK mutations at relapse of neuroblastoma J Clin Oncol 2014 32 25 2727 2734 10.1200/JCO.2013.54.0674 25071110
Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Rio Frio T, et al. Emergence of new ALK mutations at relapse of neuroblastoma. J Clin Oncol. 2014;32(25):2727–34.25071110 10.1200/JCO.2013.54.0674
9. Padovan-Merhar OM Raman P Ostrovnaya I Kalletla K Rubnitz KR Sanford EM Enrichment of targetable mutations in the relapsed neuroblastoma genome PLoS Genet 2016 12 12 e1006501 10.1371/journal.pgen.1006501 27997549
Padovan-Merhar OM, Raman P, Ostrovnaya I, Kalletla K, Rubnitz KR, Sanford EM, et al. Enrichment of targetable mutations in the relapsed neuroblastoma genome. PLoS Genet. 2016;12(12): e1006501.27997549 10.1371/journal.pgen.1006501
10. Carén H Kryh H Nethander M Sjöberg RM Träger C Nilsson S High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset Proc Natl Acad Sci U S A 2010 107 9 4323 4328 10.1073/pnas.0910684107 20145112
Carén H, Kryh H, Nethander M, Sjöberg RM, Träger C, Nilsson S, et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A. 2010;107(9):4323–8.20145112 10.1073/pnas.0910684107
11. Janoueix-Lerosey I Schleiermacher G Michels E Mosseri V Ribeiro A Lequin D Overall genomic pattern is a predictor of outcome in neuroblastoma J Clin Oncol 2009 27 7 1026 1033 10.1200/JCO.2008.16.0630 19171713
Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009;27(7):1026–33.19171713 10.1200/JCO.2008.16.0630
12. Eleveld TF Oldridge DA Bernard V Koster J Colmet Daage L Diskin SJ Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations Nat Genet 2015 47 8 864 871 10.1038/ng.3333 26121087
Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 2015;47(8):864–71.26121087 10.1038/ng.3333
13. Aktas T Kızmazoglu D Aktas S Erol A Serinan E Gokbayrak O Unraveling the mystery: next generation sequencing sheds light on neuroblastoma pathogenesis and targeted therapies Front Biosci (Landmark Ed) 2023 28 8 171 10.31083/j.fbl2808171 37664946
Aktas T, Kızmazoglu D, Aktas S, Erol A, Serinan E, Gokbayrak O, et al. Unraveling the mystery: next generation sequencing sheds light on neuroblastoma pathogenesis and targeted therapies. Front Biosci (Landmark Ed). 2023;28(8):171.37664946 10.31083/j.fbl2808171
14. George RE Sanda T Hanna M Fröhling S Luther W 2nd Zhang J Activating mutations in ALK provide a therapeutic target in neuroblastoma Nature 2008 455 7215 975 978 10.1038/nature07397 18923525
George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215):975–8.18923525 10.1038/nature07397
15. Pastorino F Capasso M Brignole C Lasorsa VA Bensa V Perri P Therapeutic targeting of ALK in neuroblastoma: experience of Italian precision medicine in pediatric oncology Cancers (Basel). 2023 15 3 560 10.3390/cancers15030560 36765519
Pastorino F, Capasso M, Brignole C, Lasorsa VA, Bensa V, Perri P, et al. Therapeutic targeting of ALK in neuroblastoma: experience of Italian precision medicine in pediatric oncology. Cancers (Basel). 2023;15(3):560.36765519 10.3390/cancers15030560
16. Kameneva P Artemov AV Kastriti ME Faure L Olsen TK Otte J Single-cell transcriptomics of human embryos identifies multiple sympathoblast lineages with potential implications for neuroblastoma origin Nat Genet 2021 53 5 694 706 10.1038/s41588-021-00818-x 33833454
Kameneva P, Artemov AV, Kastriti ME, Faure L, Olsen TK, Otte J, et al. Single-cell transcriptomics of human embryos identifies multiple sympathoblast lineages with potential implications for neuroblastoma origin. Nat Genet. 2021;53(5):694–706.33833454 10.1038/s41588-021-00818-x
17. Körber V Stainczyk SA Kurilov R Henrich K-O Hero B Brors B Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome Nat Genet 2023 55 4 619 630 10.1038/s41588-023-01332-y 36973454
Körber V, Stainczyk SA, Kurilov R, Henrich K-O, Hero B, Brors B, et al. Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome. Nat Genet. 2023;55(4):619–30.36973454 10.1038/s41588-023-01332-y
18. Jansky S Sharma AK Körber V Quintero A Toprak UH Wecht EM Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma Nat Genet 2021 53 5 683 693 10.1038/s41588-021-00806-1 33767450
Jansky S, Sharma AK, Körber V, Quintero A, Toprak UH, Wecht EM, et al. Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma. Nat Genet. 2021;53(5):683–93.33767450 10.1038/s41588-021-00806-1
19. Kildisiute G Kholosy WM Young MD Roberts K Elmentaite R van Hooff SR Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell Sci Adv 2021 7 6 eabd3311 10.1126/sciadv.abd3311 33547074
Kildisiute G, Kholosy WM, Young MD, Roberts K, Elmentaite R, van Hooff SR, et al. Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell. Sci Adv. 2021;7(6):eabd3311.33547074 10.1126/sciadv.abd3311
20. Ferguson-Smith AC Genomic imprinting: the emergence of an epigenetic paradigm Nat Rev Genet 2011 12 8 565 575 10.1038/nrg3032 21765458
Ferguson-Smith AC. Genomic imprinting: the emergence of an epigenetic paradigm. Nat Rev Genet. 2011;12(8):565–75.21765458 10.1038/nrg3032
21. Horsthemke B In brief: genomic imprinting and imprinting diseases J Pathol 2014 232 5 485 487 10.1002/path.4326 24395592
Horsthemke B. In brief: genomic imprinting and imprinting diseases. J Pathol. 2014;232(5):485–7.24395592 10.1002/path.4326
22. Randhawa GS Cui H Barletta JA Strichman-Almashanu LZ Talpaz M Kantarjian H Loss of imprinting in disease progression in chronic myelogenous leukemia Blood 1998 91 9 3144 3147 10.1182/blood.V91.9.3144 9558368
Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, et al. Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood. 1998;91(9):3144–7.9558368 10.1182/blood.V91.9.3144
23. Cui H Horon IL Ohlsson R Hamilton SR Feinberg AP Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability Nat Med 1998 4 11 1276 1280 10.1038/3260 9809551
Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med. 1998;4(11):1276–80.9809551 10.1038/3260
24. Zhao R DeCoteau JF Geyer CR Gao M Cui H Casson AG Loss of imprinting of the insulin-like growth factor II (IGF2) gene in esophageal normal and adenocarcinoma tissues Carcinogenesis 2009 30 12 2117 2122 10.1093/carcin/bgp254 19843644
Zhao R, DeCoteau JF, Geyer CR, Gao M, Cui H, Casson AG. Loss of imprinting of the insulin-like growth factor II (IGF2) gene in esophageal normal and adenocarcinoma tissues. Carcinogenesis. 2009;30(12):2117–22.19843644 10.1093/carcin/bgp254
25. Zhou J Cheng T Li X Hu J Li E Ding M Epigenetic imprinting alterations as effective diagnostic biomarkers for early-stage lung cancer and small pulmonary nodules Clin Epigenetics 2021 13 1 220 10.1186/s13148-021-01203-5 34906185
Zhou J, Cheng T, Li X, Hu J, Li E, Ding M, et al. Epigenetic imprinting alterations as effective diagnostic biomarkers for early-stage lung cancer and small pulmonary nodules. Clin Epigenetics. 2021;13(1):220.34906185 10.1186/s13148-021-01203-5
26. Henrich K-O Bender S Saadati M Dreidax D Gartlgruber M Shao C Integrative genome-scale analysis identifies epigenetic mechanisms of transcriptional deregulation in unfavorable neuroblastomas Can Res 2016 76 18 5523 5537 10.1158/0008-5472.CAN-15-2507
Henrich K-O, Bender S, Saadati M, Dreidax D, Gartlgruber M, Shao C, et al. Integrative genome-scale analysis identifies epigenetic mechanisms of transcriptional deregulation in unfavorable neuroblastomas. Can Res. 2016;76(18):5523–37.10.1158/0008-5472.CAN-15-2507
27. Olsson M Beck S Kogner P Martinsson T Carén H Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors Epigenetics 2016 11 1 74 84 10.1080/15592294.2016.1138195 26786290
Olsson M, Beck S, Kogner P, Martinsson T, Carén H. Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors. Epigenetics. 2016;11(1):74–84.26786290 10.1080/15592294.2016.1138195
28. Daenekas B, Pérez E, Boniolo F, Stefan S, Benfatto S, Sill M, et al. Conumee 2.0: enhanced copy-number variation analysis from DNA methylation arrays for humans and mice. Bioinformatics. 2024;40(2).
29. Tian Y Morris TJ Webster AP Yang Z Beck S Feber A ChAMP: updated methylation analysis pipeline for Illumina BeadChips Bioinformatics 2017 33 24 3982 3984 10.1093/bioinformatics/btx513 28961746
Tian Y, Morris TJ, Webster AP, Yang Z, Beck S, Feber A, et al. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics. 2017;33(24):3982–4.28961746 10.1093/bioinformatics/btx513
30. Hernandez Mora JR Tayama C Sánchez-Delgado M Monteagudo-Sánchez A Hata K Ogata T Characterization of parent-of-origin methylation using the Illumina Infinium MethylationEPIC array platform Epigenomics 2018 10 7 941 954 10.2217/epi-2017-0172 29962238
Hernandez Mora JR, Tayama C, Sánchez-Delgado M, Monteagudo-Sánchez A, Hata K, Ogata T, et al. Characterization of parent-of-origin methylation using the Illumina Infinium MethylationEPIC array platform. Epigenomics. 2018;10(7):941–54.29962238 10.2217/epi-2017-0172
31. Martin-Trujillo A Vidal E Monteagudo-Sánchez A Sanchez-Delgado M Moran S Hernandez Mora JR Copy number rather than epigenetic alterations are the major dictator of imprinted methylation in tumors Nat Commun 2017 8 1 467 10.1038/s41467-017-00639-9 28883545
Martin-Trujillo A, Vidal E, Monteagudo-Sánchez A, Sanchez-Delgado M, Moran S, Hernandez Mora JR, et al. Copy number rather than epigenetic alterations are the major dictator of imprinted methylation in tumors. Nat Commun. 2017;8(1):467.28883545 10.1038/s41467-017-00639-9
32. Van Loo P Nilsen G Nordgard SH Vollan HK Børresen-Dale AL Kristensen VN Analyzing cancer samples with SNP arrays Methods Mol Biol 2012 802 57 72 10.1007/978-1-61779-400-1_4 22130873
Van Loo P, Nilsen G, Nordgard SH, Vollan HK, Børresen-Dale AL, Kristensen VN, et al. Analyzing cancer samples with SNP arrays. Methods Mol Biol. 2012;802:57–72.22130873 10.1007/978-1-61779-400-1_4
33. Borgan Ø. Modeling Survival Data: Extending the Cox Model. Terry M. Therneau and Patricia M. Grambsch, Springer-Verlag, New York, 2000. No. of pages: xiii + 350. Price: $69.95. ISBN 0-387-98784-3. Statistics in Medicine. 2001;20(13):2053–4.
34. Capper D Jones DT Sill M Hovestadt V Schrimpf D Sturm D DNA methylation-based classification of central nervous system tumours Nature 2018 555 7697 469 474 10.1038/nature26000 29539639
Capper D, Jones DT, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469–74.29539639 10.1038/nature26000
35. Schepke E Löfgren M Pietsch T Olsson Bontell T Kling T Wenger A DNA methylation profiling improves routine diagnosis of paediatric central nervous system tumours: a prospective population-based study Neuropathol Appl Neurobiol 2022 48 6 e12838 10.1111/nan.12838 35892159
Schepke E, Löfgren M, Pietsch T, Olsson Bontell T, Kling T, Wenger A, et al. DNA methylation profiling improves routine diagnosis of paediatric central nervous system tumours: a prospective population-based study. Neuropathol Appl Neurobiol. 2022;48(6): e12838.35892159 10.1111/nan.12838
36. Ferreyra Vega S Olsson Bontell T Corell A Smits A Jakola AS Carén H DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas Clin Epigenetics 2021 13 1 102 10.1186/s13148-021-01085-7 33941250
Ferreyra Vega S, Olsson Bontell T, Corell A, Smits A, Jakola AS, Carén H. DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas. Clin Epigenetics. 2021;13(1):102.33941250 10.1186/s13148-021-01085-7
37. Ackermann S Cartolano M Hero B Welte A Kahlert Y Roderwieser A A mechanistic classification of clinical phenotypes in neuroblastoma Science 2018 362 6419 1165 1170 10.1126/science.aat6768 30523111
Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, et al. A mechanistic classification of clinical phenotypes in neuroblastoma. Science. 2018;362(6419):1165–70.30523111 10.1126/science.aat6768
38. Higashi M Tajiri T Kinoshita Y Tatsuta K Souzaki R Maehara Y High expressions of neuronatin isoforms in favorable neuroblastoma J Pediatr Hematol Oncol 2007 29 8 551 556 10.1097/MPH.0b013e3181256b7b 17762496
Higashi M, Tajiri T, Kinoshita Y, Tatsuta K, Souzaki R, Maehara Y, et al. High expressions of neuronatin isoforms in favorable neuroblastoma. J Pediatr Hematol Oncol. 2007;29(8):551–6.17762496 10.1097/MPH.0b013e3181256b7b
39. Yáñez Y Grau E Rodríguez-Cortez VC Hervás D Vidal E Noguera R Two independent epigenetic biomarkers predict survival in neuroblastoma Clin Epigenetics 2015 7 1 16 10.1186/s13148-015-0054-8 25767620
Yáñez Y, Grau E, Rodríguez-Cortez VC, Hervás D, Vidal E, Noguera R, et al. Two independent epigenetic biomarkers predict survival in neuroblastoma. Clin Epigenetics. 2015;7(1):16.25767620 10.1186/s13148-015-0054-8
40. Ribarska T Goering W Droop J Bastian KM Ingenwerth M Schulz WA Deregulation of an imprinted gene network in prostate cancer Epigenetics 2014 9 5 704 717 10.4161/epi.28006 24513574
Ribarska T, Goering W, Droop J, Bastian KM, Ingenwerth M, Schulz WA. Deregulation of an imprinted gene network in prostate cancer. Epigenetics. 2014;9(5):704–17.24513574 10.4161/epi.28006
41. De Faveri LE Hurst CD Platt FM Taylor CF Roulson JA Sanchez-Carbayo M Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer Br J Cancer 2013 108 6 1368 1377 10.1038/bjc.2013.104 23549060
De Faveri LE, Hurst CD, Platt FM, Taylor CF, Roulson JA, Sanchez-Carbayo M, et al. Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer. Br J Cancer. 2013;108(6):1368–77.23549060 10.1038/bjc.2013.104
42. Hayashi Y Matsuyama K Takagi K Sugiura H Yoshikawa K Arrest of cell growth by necdin, a nuclear protein expressed in postmitotic neurons Biochem Biophys Res Commun 1995 213 1 317 324 10.1006/bbrc.1995.2132 7639751
Hayashi Y, Matsuyama K, Takagi K, Sugiura H, Yoshikawa K. Arrest of cell growth by necdin, a nuclear protein expressed in postmitotic neurons. Biochem Biophys Res Commun. 1995;213(1):317–24.7639751 10.1006/bbrc.1995.2132
43. Chapman EJ Kelly G Knowles MA Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells Mol Cancer Res 2008 6 7 1154 1168 10.1158/1541-7786.MCR-07-2168 18644980
Chapman EJ, Kelly G, Knowles MA. Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells. Mol Cancer Res. 2008;6(7):1154–68.18644980 10.1158/1541-7786.MCR-07-2168
44. Taniura H Matsumoto K Yoshikawa K Physical and functional interactions of neuronal growth suppressor necdin with p53 J Biol Chem 1999 274 23 16242 16248 10.1074/jbc.274.23.16242 10347180
Taniura H, Matsumoto K, Yoshikawa K. Physical and functional interactions of neuronal growth suppressor necdin with p53. J Biol Chem. 1999;274(23):16242–8.10347180 10.1074/jbc.274.23.16242
45. Liu Y Elf SE Miyata Y Sashida G Liu Y Huang G p53 regulates hematopoietic stem cell quiescence Cell Stem Cell 2009 4 1 37 48 10.1016/j.stem.2008.11.006 19128791
Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell. 2009;4(1):37–48.19128791 10.1016/j.stem.2008.11.006
46. Vansteenkiste JF Cho BC Vanakesa T De Pas T Zielinski M Kim MS Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 2016 17 6 822 835 10.1016/S1470-2045(16)00099-1 27132212
Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(6):822–35.27132212 10.1016/S1470-2045(16)00099-1
47. Yang B O'Herrin SM Wu J Reagan-Shaw S Ma Y Bhat KM MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines Can Res 2007 67 20 9954 9962 10.1158/0008-5472.CAN-07-1478
Yang B, O’Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM, et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Can Res. 2007;67(20):9954–62.10.1158/0008-5472.CAN-07-1478
48. Zeng Z-L Wu W-J Yang J Tang Z-J Chen D-L Qiu M-Z Prognostic relevance of melanoma antigen D1 expression in colorectal carcinoma J Transl Med 2012 10 1 9 10.1186/1479-5876-10-181 22214470
Zeng Z-L, Wu W-J, Yang J, Tang Z-J, Chen D-L, Qiu M-Z, et al. Prognostic relevance of melanoma antigen D1 expression in colorectal carcinoma. J Transl Med. 2012;10:1–9.22214470 10.1186/1479-5876-10-181
49. Weeraratne SD Amani V Neiss A Teider N Scott DK Pomeroy SL miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma Neuro Oncol 2011 13 2 165 175 10.1093/neuonc/noq179 21177782
Weeraratne SD, Amani V, Neiss A, Teider N, Scott DK, Pomeroy SL, et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol. 2011;13(2):165–75.21177782 10.1093/neuonc/noq179
50. Liu X-L Zhao D Sun D-P Wang Y Li Y Qiu F-Q Adenovirus-mediated delivery of CALR and MAGE-A3 inhibits invasion and angiogenesis of glioblastoma cell line U87 J Exp Clin Cancer Res 2012 31 1 10 10.1186/1756-9966-31-8 22208663
Liu X-L, Zhao D, Sun D-P, Wang Y, Li Y, Qiu F-Q, et al. Adenovirus-mediated delivery of CALR and MAGE-A3 inhibits invasion and angiogenesis of glioblastoma cell line U87. J Exp Clin Cancer Res. 2012;31:1–10.22208663 10.1186/1756-9966-31-8
51. Plasterer C Semenikhina M Tsaih SW Flister MJ Palygin O NNAT is a novel mediator of oxidative stress that suppresses ER + breast cancer Mol Med 2023 29 1 87 10.1186/s10020-023-00673-y 37400769
Plasterer C, Semenikhina M, Tsaih SW, Flister MJ, Palygin O. NNAT is a novel mediator of oxidative stress that suppresses ER + breast cancer. Mol Med. 2023;29(1):87.37400769 10.1186/s10020-023-00673-y
52. Novotny NM Grosfeld JL Turner KE Rescorla FJ Pu X Klaunig JE Oxidative status in neuroblastoma: a source of stress? J Pediatr Surg 2008 43 2 330 334 10.1016/j.jpedsurg.2007.10.040 18280284
Novotny NM, Grosfeld JL, Turner KE, Rescorla FJ, Pu X, Klaunig JE, et al. Oxidative status in neuroblastoma: a source of stress? J Pediatr Surg. 2008;43(2):330–4.18280284 10.1016/j.jpedsurg.2007.10.040
53. Cao J Song Y Bi N Shen J Liu W Fan J DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer Can Res 2013 73 11 3326 3335 10.1158/0008-5472.CAN-12-3055
Cao J, Song Y, Bi N, Shen J, Liu W, Fan J, et al. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Can Res. 2013;73(11):3326–35.10.1158/0008-5472.CAN-12-3055
54. Lee H-S Lee K Jang H-J Lee GK Park J-L Kim S-Y Epigenetic silencing of the non-coding RNA nc886 provokes oncogenes during human esophageal tumorigenesis Oncotarget 2014 5 11 3472 10.18632/oncotarget.1927 25004084
Lee H-S, Lee K, Jang H-J, Lee GK, Park J-L, Kim S-Y, et al. Epigenetic silencing of the non-coding RNA nc886 provokes oncogenes during human esophageal tumorigenesis. Oncotarget. 2014;5(11):3472.25004084 10.18632/oncotarget.1927
55. Treppendahl MB Qiu X Søgaard A Yang X Nandrup-Bus C Hother C Allelic methylation levels of the noncoding VTRNA2–1 located on chromosome 5q31. 1 predict outcome in AML Blood J Am Soc Hematol 2012 119 1 206 216
Treppendahl MB, Qiu X, Søgaard A, Yang X, Nandrup-Bus C, Hother C, et al. Allelic methylation levels of the noncoding VTRNA2–1 located on chromosome 5q31. 1 predict outcome in AML. Blood J Am Soc Hematol. 2012;119(1):206–16.
56. Huang M Weiss WA Neuroblastoma and MYCN Cold Spring Harb Perspect Med 2013 3 10 a014415 10.1101/cshperspect.a014415 24086065
Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013;3(10): a014415.24086065 10.1101/cshperspect.a014415
57. Guo C White PS Weiss MJ Hogarty MD Thompson PM Stram DO Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas Oncogene 1999 18 35 4948 4957 10.1038/sj.onc.1202887 10490829
Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene. 1999;18(35):4948–57.10490829 10.1038/sj.onc.1202887
58. Plantaz D Vandesompele J Van Roy N Łastowska M Bown N Combaret V Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification Int J Cancer 2001 91 5 680 686 10.1002/1097-0215(200002)9999:9999<::AID-IJC1114>3.0.CO;2-R 11267980
Plantaz D, Vandesompele J, Van Roy N, Łastowska M, Bown N, Combaret V, et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer. 2001;91(5):680–6.11267980 10.1002/1097-0215(200002)9999:9999<::AID-IJC1114>3.0.CO;2-R
59. Bildik G Liang X Sutton MN Bast RC Jr Lu Z DIRAS3: an imprinted tumor suppressor gene that regulates RAS and PI3K-driven cancer growth, motility, autophagy, and tumor dormancy Mol Cancer Ther 2022 21 1 25 37 10.1158/1535-7163.MCT-21-0331 34667114
Bildik G, Liang X, Sutton MN, Bast RC Jr, Lu Z. DIRAS3: an imprinted tumor suppressor gene that regulates RAS and PI3K-driven cancer growth, motility, autophagy, and tumor dormancy. Mol Cancer Ther. 2022;21(1):25–37.34667114 10.1158/1535-7163.MCT-21-0331
60. Dai J Chen Q Li G Chen M Sun H Yan M DIRAS3, GPR171 and RAC2 were identified as the key molecular patterns associated with brain metastasis of breast cancer Front Oncol 2022 12 965136 10.3389/fonc.2022.965136 36212434
Dai J, Chen Q, Li G, Chen M, Sun H, Yan M. DIRAS3, GPR171 and RAC2 were identified as the key molecular patterns associated with brain metastasis of breast cancer. Front Oncol. 2022;12: 965136.36212434 10.3389/fonc.2022.965136
61. Kumar JD Aolymat I Tiszlavicz L Reisz Z Garalla HM Beynon R Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP-1 and TIMP-2 Oncotarget 2019 10 2 98 10.18632/oncotarget.26414 30719206
Kumar JD, Aolymat I, Tiszlavicz L, Reisz Z, Garalla HM, Beynon R, et al. Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP-1 and TIMP-2. Oncotarget. 2019;10(2):98.30719206 10.18632/oncotarget.26414
62. Huang C Dai XY Cai JX Chen J Wang BB Zhu W A screened GPR1 peptide exerts antitumor effects on triple-negative breast cancer Mol Ther Oncolytics 2020 18 602 612 10.1016/j.omto.2020.08.013 33005727
Huang C, Dai XY, Cai JX, Chen J, Wang BB, Zhu W, et al. A screened GPR1 peptide exerts antitumor effects on triple-negative breast cancer. Mol Ther Oncolytics. 2020;18:602–12.33005727 10.1016/j.omto.2020.08.013
63. Zhao R Ge Y Gong Y Li B Xiao B Zuo S NAP1L5 targeting combined with MYH9 Inhibit HCC progression through PI3K/AKT/mTOR signaling pathway Aging (Albany NY) 2022 14 22 9000 9019 10.18632/aging.204377 36374212
Zhao R, Ge Y, Gong Y, Li B, Xiao B, Zuo S. NAP1L5 targeting combined with MYH9 Inhibit HCC progression through PI3K/AKT/mTOR signaling pathway. Aging (Albany NY). 2022;14(22):9000–19.36374212 10.18632/aging.204377
64. Zhang Z He G Lv Y Liu Y Niu Z Feng Q HERC3 regulates epithelial-mesenchymal transition by directly ubiquitination degradation EIF5A2 and inhibits metastasis of colorectal cancer Cell Death Dis 2022 13 1 74 10.1038/s41419-022-04511-7 35064108
Zhang Z, He G, Lv Y, Liu Y, Niu Z, Feng Q, et al. HERC3 regulates epithelial-mesenchymal transition by directly ubiquitination degradation EIF5A2 and inhibits metastasis of colorectal cancer. Cell Death Dis. 2022;13(1):74.35064108 10.1038/s41419-022-04511-7
65. Lee K Kunkeaw N Jeon SH Lee I Johnson BH Kang GY Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity RNA 2011 17 6 1076 1089 10.1261/rna.2701111 21518807
Lee K, Kunkeaw N, Jeon SH, Lee I, Johnson BH, Kang GY, et al. Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity. RNA. 2011;17(6):1076–89.21518807 10.1261/rna.2701111
66. Pan B Yu J Liu X Upregulation of miR-886 indicates poor prognosis and promotes tumour progression of prostate cancer Andrologia 2022 54 1 e14296 10.1111/and.14296 34787343
Pan B, Yu J, Liu X. Upregulation of miR-886 indicates poor prognosis and promotes tumour progression of prostate cancer. Andrologia. 2022;54(1): e14296.34787343 10.1111/and.14296
67. Cao J Song Y Bi N Shen J Liu W Fan J DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer Cancer Res 2013 73 11 3326 3335 10.1158/0008-5472.CAN-12-3055 23592755
Cao J, Song Y, Bi N, Shen J, Liu W, Fan J, et al. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer Res. 2013;73(11):3326–35.23592755 10.1158/0008-5472.CAN-12-3055
68. Temple IK, Mackay DJG. Diabetes Mellitus, 6q24-Related Transient Neonatal. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews(®). Seattle: University of Washington.
69. Copyright © 1993–2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved; 1993.
70. Chen Y Tang M Xiong J Gao Q Cao W Huang J GRB10 is a novel oncogene associated with cell proliferation and prognosis in glioma Cancer Cell Int 2022 22 1 223 10.1186/s12935-022-02636-5 35790975
Chen Y, Tang M, Xiong J, Gao Q, Cao W, Huang J. GRB10 is a novel oncogene associated with cell proliferation and prognosis in glioma. Cancer Cell Int. 2022;22(1):223.35790975 10.1186/s12935-022-02636-5
71. Okabe H Satoh S Furukawa Y Kato T Hasegawa S Nakajima Y Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1 Can Res 2003 63 12 3043 3048
Okabe H, Satoh S, Furukawa Y, Kato T, Hasegawa S, Nakajima Y, et al. Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Can Res. 2003;63(12):3043–8.
72. Peng Y-P Zhu Y Yin L-D Zhang J-J Wei J-S Liu X PEG10 overexpression induced by E2F–1 promotes cell proliferation, migration, and invasion in pancreatic cancer J Exp Clin Cancer Res 2017 36 1 12 10.1186/s13046-017-0500-x 28049532
Peng Y-P, Zhu Y, Yin L-D, Zhang J-J, Wei J-S, Liu X, et al. PEG10 overexpression induced by E2F–1 promotes cell proliferation, migration, and invasion in pancreatic cancer. J Exp Clin Cancer Res. 2017;36:1–12.28049532 10.1186/s13046-017-0500-x
73. Li C-M Margolin AA Salas M Memeo L Mansukhani M Hibshoosh H PEG10 is a c-MYC target gene in cancer cells Can Res 2006 66 2 665 672 10.1158/0008-5472.CAN-05-1553
Li C-M, Margolin AA, Salas M, Memeo L, Mansukhani M, Hibshoosh H, et al. PEG10 is a c-MYC target gene in cancer cells. Can Res. 2006;66(2):665–72.10.1158/0008-5472.CAN-05-1553
74. Liu D-C Yang Z-L Jiang S Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma Pathol Oncol Res 2011 17 859 866 10.1007/s12253-011-9394-7 21455631
Liu D-C, Yang Z-L, Jiang S. Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Pathol Oncol Res. 2011;17:859–66.21455631 10.1007/s12253-011-9394-7
75. Gao S Lu X Ma J Zhou Q Tang R Fu Z Comprehensive analysis of lncRNA and miRNA regulatory network reveals potential prognostic non-coding RNA involved in breast cancer progression Front Genet 2021 12 621809 10.3389/fgene.2021.621809 34220926
Gao S, Lu X, Ma J, Zhou Q, Tang R, Fu Z, et al. Comprehensive analysis of lncRNA and miRNA regulatory network reveals potential prognostic non-coding RNA involved in breast cancer progression. Front Genet. 2021;12: 621809.34220926 10.3389/fgene.2021.621809
76. Xu WW Liao L Dai W Zheng CC Tan XP He Y Genome-wide CRISPR/Cas9 screening identifies a targetable MEST-PURA interaction in cancer metastasis EBioMedicine 2023 92 104587 10.1016/j.ebiom.2023.104587 37149929
Xu WW, Liao L, Dai W, Zheng CC, Tan XP, He Y, et al. Genome-wide CRISPR/Cas9 screening identifies a targetable MEST-PURA interaction in cancer metastasis. EBioMedicine. 2023;92: 104587.37149929 10.1016/j.ebiom.2023.104587
77. Zhao R Wei W Zhen L WGCNA-based identification of potential targets and pathways in response to treatment in locally advanced breast cancer patients Open Med (Wars) 2023 18 1 20230651 10.1515/med-2023-0651 36896338
Zhao R, Wei W, Zhen L. WGCNA-based identification of potential targets and pathways in response to treatment in locally advanced breast cancer patients. Open Med (Wars). 2023;18(1):20230651.36896338 10.1515/med-2023-0651
78. Boot A Oosting J Doorn S Ouahoud S Ventayol Garcia M Ruano D Allelic switching of DLX5, GRB10, and SVOPL during colorectal cancer tumorigenesis Int J Genomics 2019 2019 1287671 10.1155/2019/1287671 31093489
Boot A, Oosting J, Doorn S, Ouahoud S, Ventayol Garcia M, Ruano D, et al. Allelic switching of DLX5, GRB10, and SVOPL during colorectal cancer tumorigenesis. Int J Genomics. 2019;2019:1287671.31093489 10.1155/2019/1287671
79. Lu Q Ding Y Li Y Lu Q 5-HT receptor agonist Valerenic Acid enhances the innate immunity signal and suppresses glioblastoma cell growth and invasion Int J Biol Sci 2020 16 12 2104 2115 10.7150/ijbs.44906 32549758
Lu Q, Ding Y, Li Y, Lu Q. 5-HT receptor agonist Valerenic Acid enhances the innate immunity signal and suppresses glioblastoma cell growth and invasion. Int J Biol Sci. 2020;16(12):2104–15.32549758 10.7150/ijbs.44906
80. Zhang X Cai J Zheng Z Polin L Lin Z Dandekar A A novel ER–microtubule-binding protein, ERLIN2, stabilizes Cyclin B1 and regulates cell cycle progression Cell Discovery 2015 1 1 15024 10.1038/celldisc.2015.24 27462423
Zhang X, Cai J, Zheng Z, Polin L, Lin Z, Dandekar A, et al. A novel ER–microtubule-binding protein, ERLIN2, stabilizes Cyclin B1 and regulates cell cycle progression. Cell Discovery. 2015;1(1):15024.27462423 10.1038/celldisc.2015.24
81. Zhang Y Liu S Wang H Yang W Li F Yang F Elevated NIBP/TRAPPC9 mediates tumorigenesis of cancer cells through NFκB signaling Oncotarget 2015 6 8 6160 6178 10.18632/oncotarget.3349 25704885
Zhang Y, Liu S, Wang H, Yang W, Li F, Yang F, et al. Elevated NIBP/TRAPPC9 mediates tumorigenesis of cancer cells through NFκB signaling. Oncotarget. 2015;6(8):6160–78.25704885 10.18632/oncotarget.3349
82. Kim HS Li A Ahn S Song H Zhang W Inositol Polyphosphate-5-phosphatase F (INPP5F) inhibits STAT3 activity and suppresses gliomas tumorigenicity Sci Rep 2014 4 1 7330 10.1038/srep07330 25476455
Kim HS, Li A, Ahn S, Song H, Zhang W. Inositol Polyphosphate-5-phosphatase F (INPP5F) inhibits STAT3 activity and suppresses gliomas tumorigenicity. Sci Rep. 2014;4(1):7330.25476455 10.1038/srep07330
83. Zhang K Luo Z Zhang Y Zhang L Wu L Liu L Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer Cancer Biomark 2016 17 2 187 194 10.3233/CBM-160630 27540977
Zhang K, Luo Z, Zhang Y, Zhang L, Wu L, Liu L, et al. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer. Cancer Biomark. 2016;17(2):187–94.27540977 10.3233/CBM-160630
84. Yang W Ning N Jin X The lncRNA H19 promotes cell proliferation by competitively binding to miR-200a and derepressing β-catenin expression in colorectal cancer BioMed Res Int 2017 2017 1
Yang W, Ning N, Jin X. The lncRNA H19 promotes cell proliferation by competitively binding to miR-200a and derepressing β-catenin expression in colorectal cancer. BioMed Res Int. 2017;2017:1.
85. Zhao Y Feng C Li Y Ma Y Cai R LncRNA H19 promotes lung cancer proliferation and metastasis by inhibiting miR-200a function Mol Cell Biochem 2019 460 1 8 10.1007/s11010-019-03564-1 31187349
Zhao Y, Feng C, Li Y, Ma Y, Cai R. LncRNA H19 promotes lung cancer proliferation and metastasis by inhibiting miR-200a function. Mol Cell Biochem. 2019;460:1–8.31187349 10.1007/s11010-019-03564-1
86. Zhang W, Zhou K, Zhang X, Wu C, Deng D, Yao Z. Roles of the H19/microRNA‑675 axis in the proliferation and epithelial‑mesenchymal transition of human cutaneous squamous cell carcinoma cells. Oncol Rep. 2021;45(4).
87. Gao S Lin Z Li C Wang Y Yang L Zou B lncINS-IGF2 promotes cell proliferation and migration by promoting G1/S transition in lung cancer Technol Cancer Res Treat 2019 18 1533033818823029 10.1177/1533033818823029 30803359
Gao S, Lin Z, Li C, Wang Y, Yang L, Zou B, et al. lncINS-IGF2 promotes cell proliferation and migration by promoting G1/S transition in lung cancer. Technol Cancer Res Treat. 2019;18:1533033818823029.30803359 10.1177/1533033818823029
88. Gronbaek H Flyvbjerg A Mellemkjaer L Tjonneland A Christensen J Sorensen H Serum insulin-like growth factors, insulin-like growth factor binding proteins and breast cancer risk in postmenopausal women Cancer Epidemiol Biomark Prev 2004 13 1759 1764 10.1158/1055-9965.1759.13.11
Gronbaek H, Flyvbjerg A, Mellemkjaer L, Tjonneland A, Christensen J, Sorensen H, et al. Serum insulin-like growth factors, insulin-like growth factor binding proteins and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomark Prev. 2004;13:1759–64.10.1158/1055-9965.1759.13.11
89. Guerra F Eijan A Puricelli L Alonso D Bal de Kier Joffe E Kornblihgtt A Varying patterns of expression of insulin-like growth factors-I and-II and their receptors in murine mammary adenocarcinoma of different metastasizing ability Int J Cancer 1996 65 812 820 10.1002/(SICI)1097-0215(19960315)65:6<812::AID-IJC18>3.0.CO;2-5 8631597
Guerra F, Eijan A, Puricelli L, Alonso D, Bal de Kier Joffe E, Kornblihgtt A, et al. Varying patterns of expression of insulin-like growth factors-I and-II and their receptors in murine mammary adenocarcinoma of different metastasizing ability. Int J Cancer. 1996;65:812–20.8631597 10.1002/(SICI)1097-0215(19960315)65:6<812::AID-IJC18>3.0.CO;2-5
90. Hakam A Yeatman T Lu L Mora L Marcet G Nicosia S Expression of insulin-like growth factor-1 receptor in human colorectal cancer Hum Pathol 1999 30 1128 1133 10.1016/S0046-8177(99)90027-8 10534157
Hakam A, Yeatman T, Lu L, Mora L, Marcet G, Nicosia S, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol. 1999;30:1128–33.10534157 10.1016/S0046-8177(99)90027-8
91. Kim K Bae S Lee O Bae M Lee M Park B Insulin-like growth factor-II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma Can Res 1998 58 348 351
Kim K, Bae S, Lee O, Bae M, Lee M, Park B. Insulin-like growth factor-II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Can Res. 1998;58:348–51.
92. Chen Q Sun T Wang F Gong B Xie W Ma M Long noncoding RNA IGF2AS is acting as an epigenetic tumor suppressor in human prostate cancer Urology 2019 124 310.e1 e8 10.1016/j.urology.2018.11.002 30423304
Chen Q, Sun T, Wang F, Gong B, Xie W, Ma M, et al. Long noncoding RNA IGF2AS is acting as an epigenetic tumor suppressor in human prostate cancer. Urology. 2019;124:310.e1-e8.30423304 10.1016/j.urology.2018.11.002
93. Liu G Shi L Wang B Wu Z Zhao H Zhao T Role of oncogenic long noncoding RNA KCNQ1OT1 in colon cancer Oncol Res 2024 32 3 585 596 10.32604/or.2023.029349 38361755
Liu G, Shi L, Wang B, Wu Z, Zhao H, Zhao T, et al. Role of oncogenic long noncoding RNA KCNQ1OT1 in colon cancer. Oncol Res. 2024;32(3):585–96.38361755 10.32604/or.2023.029349
94. De Rosa P Severi F Zadran SK Russo M Aloisi S Rigamonti A MYCN amplification, along with wild-type RB1 expression, enhances CDK4/6 inhibitors’ efficacy in neuroblastoma cells Int J Mol Sci 2023 24 6 5408 10.3390/ijms24065408 36982482
De Rosa P, Severi F, Zadran SK, Russo M, Aloisi S, Rigamonti A, et al. MYCN amplification, along with wild-type RB1 expression, enhances CDK4/6 inhibitors’ efficacy in neuroblastoma cells. Int J Mol Sci. 2023;24(6):5408.36982482 10.3390/ijms24065408
95. Xie B Tan G Ren J Lu W Pervaz S Ren X RB1 is an immune-related prognostic biomarker for ovarian cancer Front Oncol 2022 12 830908 10.3389/fonc.2022.830908 35299734
Xie B, Tan G, Ren J, Lu W, Pervaz S, Ren X, et al. RB1 is an immune-related prognostic biomarker for ovarian cancer. Front Oncol. 2022;12: 830908.35299734 10.3389/fonc.2022.830908
96. Miao C Tsujino T Takai T Gui F Tsutsumi T Sztupinszki Z RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer Sci Adv 2022 8 7 eabl9794 10.1126/sciadv.abl9794 35179959
Miao C, Tsujino T, Takai T, Gui F, Tsutsumi T, Sztupinszki Z, et al. RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer. Sci Adv. 2022;8(7):eabl9794.35179959 10.1126/sciadv.abl9794
97. Offin M Chan JM Tenet M Rizvi HA Shen R Riely GJ Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes J Thorac Oncol 2019 14 10 1784 1793 10.1016/j.jtho.2019.06.002 31228622
Offin M, Chan JM, Tenet M, Rizvi HA, Shen R, Riely GJ, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol. 2019;14(10):1784–93.31228622 10.1016/j.jtho.2019.06.002
98. Jiang Z Jones R Liu JC Deng T Robinson T Chung PE RB1 and p53 at the crossroad of EMT and triple-negative breast cancer Cell Cycle 2011 10 10 1563 1570 10.4161/cc.10.10.15703 21502814
Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. 2011;10(10):1563–70.21502814 10.4161/cc.10.10.15703
99. Xu J Wang X Zhu C Wang K A review of current evidence about lncRNA MEG3: a tumor suppressor in multiple cancers Front Cell Dev Biol 2022 10 997633 10.3389/fcell.2022.997633 36544907
Xu J, Wang X, Zhu C, Wang K. A review of current evidence about lncRNA MEG3: a tumor suppressor in multiple cancers. Front Cell Dev Biol. 2022;10: 997633.36544907 10.3389/fcell.2022.997633
100. Du Z Tan F Chen J Wang B Liu Y Zhao F MEG8: an indispensable long non-coding RNA in multiple cancers Curr Pharm Des 2022 28 20 1688 1694 10.2174/1381612828666220516090245 35578848
Du Z, Tan F, Chen J, Wang B, Liu Y, Zhao F, et al. MEG8: an indispensable long non-coding RNA in multiple cancers. Curr Pharm Des. 2022;28(20):1688–94.35578848 10.2174/1381612828666220516090245
101. Li K, Zheng X, Tang H, Zang YS, Zeng C, Liu X, et al. E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer. J Exp Med. 2021;218(8).
102. Arora M Kumari S Singh J Chopra A Chauhan SS Downregulation of brain enriched type 2 MAGEs is associated with immune infiltration and poor prognosis in glioma Front Oncol 2020 10 573378 10.3389/fonc.2020.573378 33425727
Arora M, Kumari S, Singh J, Chopra A, Chauhan SS. Downregulation of brain enriched type 2 MAGEs is associated with immune infiltration and poor prognosis in glioma. Front Oncol. 2020;10: 573378.33425727 10.3389/fonc.2020.573378
103. Chapman EJ Knowles MA Necdin: a multi functional protein with potential tumor suppressor role? Mol Carcinogenesis 2009 48 11 975 981 10.1002/mc.20567
Chapman EJ, Knowles MA. Necdin: a multi functional protein with potential tumor suppressor role? Mol Carcinogenesis. 2009;48(11):975–81.10.1002/mc.20567
104. Ji M Ren L Lv Y Lao X Feng Q Tang W Small nuclear ribonucleoprotein polypeptide N accelerates malignant progression and poor prognosis in colorectal cancer transcriptionally regulated by E2F8 Front Oncol 2020 10 561287 10.3389/fonc.2020.561287 33224876
Ji M, Ren L, Lv Y, Lao X, Feng Q, Tang W, et al. Small nuclear ribonucleoprotein polypeptide N accelerates malignant progression and poor prognosis in colorectal cancer transcriptionally regulated by E2F8. Front Oncol. 2020;10: 561287.33224876 10.3389/fonc.2020.561287
105. Saville B Poukka H Wormke M Janne OA Palvimo JJ Stoner M Cooperative coactivation of estrogen receptor alpha in ZR-75 human breast cancer cells by SNURF and TATA-binding protein J Biol Chem 2002 277 4 2485 2497 10.1074/jbc.M109021200 11696545
Saville B, Poukka H, Wormke M, Janne OA, Palvimo JJ, Stoner M, et al. Cooperative coactivation of estrogen receptor alpha in ZR-75 human breast cancer cells by SNURF and TATA-binding protein. J Biol Chem. 2002;277(4):2485–97.11696545 10.1074/jbc.M109021200
106. Alfaro-Arnedo E López IP Piñeiro-Hermida S Canalejo M Gotera C Sola JJ IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression Oncogene 2022 41 28 3625 3639 10.1038/s41388-022-02376-w 35688943
Alfaro-Arnedo E, López IP, Piñeiro-Hermida S, Canalejo M, Gotera C, Sola JJ, et al. IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression. Oncogene. 2022;41(28):3625–39.35688943 10.1038/s41388-022-02376-w
107. Yu J Liang QY Wang J Cheng Y Wang S Poon TCW Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer Oncogene 2013 32 3 307 317 10.1038/onc.2012.54 22370639
Yu J, Liang QY, Wang J, Cheng Y, Wang S, Poon TCW, et al. Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer. Oncogene. 2013;32(3):307–17.22370639 10.1038/onc.2012.54
108. Vedeld HM Nesbakken A Lothe RA Lind GE Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer Clin Epigenetics 2018 10 70 10.1186/s13148-018-0503-2 29854011
Vedeld HM, Nesbakken A, Lothe RA, Lind GE. Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer. Clin Epigenetics. 2018;10:70.29854011 10.1186/s13148-018-0503-2
109. Zhang G Lv X Yang Q Liu H Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma BMC Cancer 2022 22 1 888 10.1186/s12885-022-09987-2 35964022
Zhang G, Lv X, Yang Q, Liu H. Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma. BMC Cancer. 2022;22(1):888.35964022 10.1186/s12885-022-09987-2
110. Han F Hu M Zhang L Fan X Wang J Lou Z A-to-I RNA editing of BLCAP promotes cell proliferation by losing the inhibitory of Rb1 in colorectal cancer Exp Cell Res 2022 417 2 113209 10.1016/j.yexcr.2022.113209 35605649
Han F, Hu M, Zhang L, Fan X, Wang J, Lou Z, et al. A-to-I RNA editing of BLCAP promotes cell proliferation by losing the inhibitory of Rb1 in colorectal cancer. Exp Cell Res. 2022;417(2): 113209.35605649 10.1016/j.yexcr.2022.113209
111. Gromova I Svensson S Gromov P Moreira JM Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer PLoS ONE 2017 12 11 e0188827 10.1371/journal.pone.0188827 29190807
Gromova I, Svensson S, Gromov P, Moreira JM. Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer. PLoS ONE. 2017;12(11): e0188827.29190807 10.1371/journal.pone.0188827
112. Xiong H, Chen G, Fang K, Gu W, Qiu F. Neuronatin promotes the progression of non-small cell lung cancer by activating the NF-κB signaling. Curr Cancer Drug Targets. 2024.
113. Xu DS Yang C Proescholdt M Bründl E Brawanski A Fang X Neuronatin in a subset of glioblastoma multiforme tumor progenitor cells is associated with increased cell proliferation and shorter patient survival PLoS ONE 2012 7 5 e37811 10.1371/journal.pone.0037811 22624064
Xu DS, Yang C, Proescholdt M, Bründl E, Brawanski A, Fang X, et al. Neuronatin in a subset of glioblastoma multiforme tumor progenitor cells is associated with increased cell proliferation and shorter patient survival. PLoS ONE. 2012;7(5): e37811.22624064 10.1371/journal.pone.0037811
114. Yokota N Mainprize TG Taylor MD Kohata T Loreto M Ueda S Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization Oncogene 2004 23 19 3444 3453 10.1038/sj.onc.1207475 15064731
Yokota N, Mainprize TG, Taylor MD, Kohata T, Loreto M, Ueda S, et al. Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene. 2004;23(19):3444–53.15064731 10.1038/sj.onc.1207475
115. Gurvich N Perna F Farina A Voza F Menendez S Hurwitz J L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability Proc Natl Acad Sci U S A 2010 107 52 22552 22557 10.1073/pnas.1017092108 21149733
Gurvich N, Perna F, Farina A, Voza F, Menendez S, Hurwitz J, et al. L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. Proc Natl Acad Sci U S A. 2010;107(52):22552–7.21149733 10.1073/pnas.1017092108
116. Ding H Zhang X Su Y Jia C Dai C GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation Cell Mol Biol Lett 2020 25 1 8 10.1186/s11658-020-00204-1 32123532
Ding H, Zhang X, Su Y, Jia C, Dai C. GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation. Cell Mol Biol Lett. 2020;25(1):8.32123532 10.1186/s11658-020-00204-1
117. Koedoot E van Steijn E Vermeer M González-Prieto R Vertegaal ACO Martens JWM Splicing factors control triple-negative breast cancer cell mitosis through SUN2 interaction and sororin intron retention J Exp Clin Cancer Res 2021 40 1 82 10.1186/s13046-021-01863-4 33648524
Koedoot E, van Steijn E, Vermeer M, González-Prieto R, Vertegaal ACO, Martens JWM, et al. Splicing factors control triple-negative breast cancer cell mitosis through SUN2 interaction and sororin intron retention. J Exp Clin Cancer Res. 2021;40(1):82.33648524 10.1186/s13046-021-01863-4
